

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
28 February 2002 (28.02.2002)

PCT

(10) International Publication Number
WO 02/16394 A1(51) International Patent Classification⁷: **C07J 41/00**,
A61K 31/565, A61P 35/00

Sterix Limited, Magdalen Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA (GB).

(21) International Application Number: PCT/GB01/03705

(74) Agents: **ALCOCK, David** et al.; D Young & Co, 21 New Fetter Lane, London EC4A 1DA (GB).

(22) International Filing Date: 17 August 2001 (17.08.2001)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0020498.2 18 August 2000 (18.08.2000) GB(71) Applicant (*for all designated States except US*): **STERIX LIMITED** [GB/GB]; Magdalen Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA (GB).(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **POTTER, Barry, Victor, Lloyd** [GB/GB]; Sterix Limited, Magdalen Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA (GB). **REED, Michael, John** [GB/GB];


Published:

— with international search report


[Continued on next page]

(54) Title: THIOETHER-SULPHAMATE STEROIDS AS STEROID SULPHATASE INHIBITORS AND ANTI-CANCER COMPOUNDS

A flexible entry to substituted estrones



Ability to selectively access a wide range of substituted estrones through the utilization of a 2-protected estrone intermediate which can be obtained in a regioselective manner and subsequently quenched with a wide range of electrophiles. This is an efficient way for us to access 2-Methoxy and 2-Ethyl estrones. It has also allowed us to synthesize several new classes of compounds, some of which display high biological activity.



(57) Abstract: There is provided a compound of Formula (I) wherein X is a ring having at least 4 atoms in the ring; K is a hydrocarbyl group; R¹ is an optional group of the formula -L¹-S-R^{1'}, wherein L¹ is an optional linker group and R^{1'} is a hydrocarbyl group; R² is an optional group of the formula -L²-S-R^{2'}, wherein L² is an optional linker group and R^{2'} is a hydrocarbyl group; R³ is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; wherein at least one of R¹ and R² is present, and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity and/or is capable of acting as a modulator of cell cycling and/or as a modulator of apoptosis and/or as a modulator of cell growth.



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

THIOETHER-SULPHAMATE STEROIDS AS STEROID SULPHATASE INHIBITORS AND ANTI-CANCER COMPOUNDS

FIELD OF INVENTION

5 The present invention relates to a compound.

In particular the present invention relates to a compound and to a pharmaceutical composition comprising the compound. The present invention also relates to the use of the compound or composition in therapy applications.

10


BACKGROUND TO THE INVENTION

Evidence suggests that oestrogens are the major mitogens involved in promoting the growth of tumours in endocrine-dependent tissues, such as the breast and endometrium. Although plasma oestrogen concentrations are similar in women with or without breast cancer, breast tumour oestrone and oestradiol levels are significantly higher than in normal breast tissue or blood. *In situ* synthesis of oestrogen is thought to make an important contribution to the high levels of oestrogens in tumours and therefore inhibitors, in particular specific inhibitors, of oestrogen biosynthesis are of potential value for the treatment of endocrine-dependent tumours.

Over the past two decades, there has been considerable interest in the development of inhibitors of the aromatase pathway - which converts the androgen precursor androstenedione to oestrone. However, there is now evidence that the oestrone sulphatase (E1-STS) pathway, i.e. the hydrolysis of oestrone sulphate to oestrone (E1S to E1), as opposed to the aromatase pathway, is the major source of oestrogen in breast tumours. This theory is supported by a modest reduction of plasma oestrogen concentration in postmenopausal women with breast cancer treated by aromatase inhibitors, such as aminoglutethimide and 4-hydroxyandrostenedione, and also by the fact that plasma E1S concentration in these aromatase inhibitor-treated patients remains relatively high. The long half-life of E1S in blood (10-12 h) compared with the unconjugated oestrogens (20 min) and high levels of steroid sulphatase activity in liver and, normal and malignant breast tissues, also lend support to this theory.

35 PCT/GB92/01587 teaches novel steroid sulphatase inhibitors and pharmaceutical

compositions containing them for use in the treatment of oestrone dependent tumours, especially breast cancer. These steroid sulphatase inhibitors are sulphamate esters, such as N,N-dimethyl oestrone-3-sulphamate and, preferably, oestrone-3-sulphamate (otherwise known as "EMATE"). EMATE has the following structure:



It is known that EMATE is a potent E1-STS inhibitor as it displays more than 99% inhibition of E1-STS activity in intact MCF-7 cells at 0.1 mM. EMATE also inhibits the E1-STS enzyme in a time- and concentration-dependent manner, indicating that it acts as an active site-directed inactivator. Although EMATE was originally designed for the inhibition of E1-STS, it also inhibits dehydroepiandrosterone sulphatase (DHA-STS), which is an enzyme that is believed to have a pivotal role in regulating the biosynthesis of the oestrogenic steroid androstenediol. Also, there is now evidence to suggest that androstenediol may be of even greater importance as a promoter of breast tumour growth. EMATE is also active in vivo as almost complete inhibition of rat liver E1-STS (99%) and DHA-STS (99%) activities resulted when it is administered either orally or subcutaneously. In addition, EMATE has been shown to have a memory enhancing effect in rats. Studies in mice have suggested an association between DHA-STS activity and the regulation of part of the immune response. It is thought that this may also occur in humans. The bridging O-atom of the sulphamate moiety in EMATE is important for inhibitory activity. Thus, when the 3-O-atom is replaced by other heteroatoms as in oestrone-3-N-sulphamate and oestrone-3-S-sulphamate, these analogues are weaker non-time-dependent inactivators.

Although optimal potency for inhibition of E1-STS may have been attained in EMATE, it is possible that oestrone may be released during sulphatase inhibition and that EMATE and its oestradiol congener may possess oestrogenic activity.

Ahmed *et al* (Biochem Biophys Res Commun 1999 Jan 27;254(3):811-5) report on a

structure-activity relationship study of steroidal and nonsteroidal inhibitors of STS.

The present invention seeks to provide novel compounds suitable for the inhibition of E1-STs as well as other therapeutic applications.

5

SUMMARY ASPECTS OF THE PRESENT INVENTION

The present invention is based on the surprising finding that certain compounds could be used as effective steroid sulphatase inhibitors and/or as agents that can influence cell cycling and/or as agents that can influence apoptosis.

10

In one aspect, the present invention is based on the surprising finding that certain hydrocarbylsulphanyl compounds could be used as effective steroid sulphatase inhibitors and/or as modulators of cell cycling and/or as modulators of apoptosis.

15

The term "hydrocarbylsulphanyl" means a group that comprises at least hydrocarbyl group (as herein defined) and sulphur. That sulphur group may be optionally oxidised.

The hydrocarbylsulphanyl compounds comprise at least one hydrocarbylsulphanyl group that is a substituent of a ring system compound. The ring system compounds comprise at least one ring component. That ring component comprises at least 4 atoms in the ring. Typically, those 4 atoms will be carbon atoms. Thus, typically, that ring component will be a hydrocarbyl group. The ring system compound also includes one or more of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group as further substituent(s) on the ring system. At least one of the sulphamate group, the phosphonate group, the thiophosphonate group, the sulphonate group or the sulphonamide group is a substituent on the ring component. In a preferred aspect, the hydrocarbylsulphanyl group(s) will be substituents on atom(s) that are adjacent to the atom which bears the at least one sulphamate group, phosphonate group, thiophosphonate group, sulphonate group or sulphonamide group.


The compounds of the present invention may comprise other substituents. These other substituents may, for example, further increase the activity of the compounds of the present invention and/or increase stability (*ex vivo* and/or *in vivo*).

35

DETAILED ASPECTS OF THE PRESENT INVENTION

According to one aspect of the present invention, there is provided a compound of

5 Formula I



Formula I

wherein X is a ring having at least 4 atoms in the ring; K is a hydrocarbyl group; R¹ is an optional group of the formula -L¹-S-R^{1'}, wherein L¹ is an optional linker group and R^{1'} is a hydrocarbyl group; R² is an optional group of the formula -L²-S-R^{2'}, wherein L² is an optional linker group and R^{2'} is a hydrocarbyl group; R³ is any one of a sulphonate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group; wherein at least one of R¹ and R² is present; and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity and/or is capable of acting as a modulator of cell cycling and/or as a modulator of apoptosis and/or as a modulator of cell growth (e.g growth inhibitor).

15

According to one aspect of the present invention, there is provided a method comprising (a) performing a steroid sulphatase assay with one or more candidate compounds of Formula I; (b) determining whether one or more of said candidate compounds is/are capable of modulating STS activity and/or cell cycling and/or cell growth and/or apoptosis; and (c) selecting one or more of said candidate compounds that is/are capable of modulating STS activity and/or cell cycling and/or cell growth and/or apoptosis.

20

According to one aspect of the present invention, there is provided a method comprising (a) performing a steroid sulphatase assay with one or more candidate compounds having of Formula I; (b) determining whether one or more of said candidate compounds is/are capable of inhibiting STS activity; and (c) selecting one or more of said candidate compounds that is/are capable of inhibiting STS activity and/or cell cycling and/or cell growth and/or apoptosis.

25

30

In any one of the methods of the present invention, one or more additional steps may be present. For example, the method may also include the step of modifying the identified candidate compound (such as by chemical and/or enzymatic techniques) and the optional additional step of testing that modified compound for STS inhibition effects (which may be to see if the effect is greater or different). By way of further example, the method may also include the step of determining the structure (such as by use of crystallographic techniques) of the identified candidate compound and then performing computer modelling studies – such as to further increase its STS inhibitory action. Thus, the present invention also encompasses a computer having a dataset (such as the crystallographic co-ordinates) for said identified candidate compound. The present invention also encompasses that identified candidate compound when presented on a computer screen for the analysis thereof – such as protein binding studies.

According to one aspect of the present invention, there is provided a compound identified by the method of the present invention.

According to one aspect of the present invention, there is provided a compound according to the present invention for use in medicine.

According to one aspect of the present invention, there is provided a pharmaceutical composition comprising the compound according to the present invention optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

According to one aspect of the present invention, there is provided the use of a compound according to the present invention in the manufacture of a medicament for use in the therapy of a condition or disease associated with STS and/or cell cycling and/or apoptosis and/or cell growth.

According to one aspect of the present invention, there is provided the use of a compound according to the present invention in the manufacture of a medicament for use in the therapy of a condition or disease associated with adverse STS levels and/or cell cycling and/or apoptosis and/or cell growth.


The present invention also encompasses the novel compounds of the present invention (such as those presented herein), as well as processes for making same (such as the

processes presented herein) as well as novel intermediates (such as those presented herein) for use in those processes.

For ease of reference, these and further aspects of the present invention are now
 5 discussed under appropriate section headings. However, the teachings under each section are not necessarily limited to each particular section.

PREFERABLE ASPECTS

10 Preferably the compound of the present invention is of Formula II




Formula II

wherein each of X, K, R¹, R³, R², and R² have the above-mentioned meanings.

Preferably the compound of the present invention is of Formula III


15



Formula III

wherein each of X, K, R¹, R³, R², and R² have the above-mentioned meanings.

20 Preferably the compound of the present invention is of Formula IV



Formula IV

wherein each of X, K, R¹, R³, R², and R² have the above-mentioned meanings.

meanings.

Preferably, X in combination with K mimics a steroidal structure.

5 Preferably, K is a cyclic group.

Preferably, X is a six-membered ring.

Preferably, the ring X has six carbon atoms in the ring.

10

Preferably, group K and ring X are a steroid ring structure or a substituted derivative thereof.

Preferably, the R³ group is at position 3 of the ring X.

15

Preferably, R³ is a sulphamate group.

Preferably, the R¹ is at position 2 of the ring X.

20 Preferably, the R² is at position 4 of the ring X.

Preferably, R^{1'} and/or R^{2'} are alkyl groups.

Preferably, R^{1'} and/or R^{2'} are C₁-C₁₀, preferably C₁-C₆, preferably C₁-C₃ alkyl groups.

25

Preferably, R^{1'} and/or R^{2'} are -CH₃ or -CH₂CH₃.

Preferably the group K and the ring X together will contain, inclusive of all substituents, a maximum of about 50 carbon atoms, more usually no more than about 30 to 40 carbon atoms.

30

For some compounds of the present invention, it is highly preferred that X is a steroidal ring; wherein at least the D ring of X is substituted.

35 For some compounds of the present invention, it is highly preferred that X is a steroidal

ring; wherein at least the 17 position of the D ring of X is substituted.

For some compounds of the present invention, it is highly preferred that X is a steroidal ring; wherein at least the 17 position of the D ring of X is substituted with a hydrocarbyl group, preferably an aryl group.

For some compounds of the present invention, it is highly preferred that X is a steroidal ring; wherein at least the A ring of X is substituted with an alkoxy group.

10 For some compounds of the present invention, it is highly preferred that X is a steroidal ring; wherein at least the 2 position of the A ring of X is substituted with an alkoxy group.

Preferably the alkoxy group is methoxy.

15 For some compounds of the present invention, it is highly preferred that X is a steroidal ring; wherein at least the A ring of X is substituted with an hydrocarbyl group.

For some compounds of the present invention, it is highly preferred that X is a steroidal ring; wherein at least the 2 position of the A ring of X is substituted with an alkyl group.

20

Preferably the alkyl group is ethyl.

For some compounds of the present invention, it is highly preferred that the compound comprises at least two or more of sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group.

25

For some compounds of the present invention, it is highly preferred that the compound comprises at least two sulphamate groups.

30 For some compounds of the present invention, it is highly preferred that the compound comprises at least two sulphamate groups, wherein said sulphamate groups are not on the same ring.

For some compounds of the present invention, it is highly preferred that X is a steroidal ring; wherein the A ring of X comprises at least one sulphamate group and wherein the

35

D ring of X comprises at least one sulphamate group.

For some applications, preferably the compounds have no, or a minimal, oestrogenic effect.

5

For some applications, preferably the compounds have an oestrogenic effect.


For some applications, preferably the compounds have a reversible action.

10 For some applications, preferably the compounds have an irreversible action.


In one embodiment, the compounds of the present invention are useful for the treatment of breast cancer.

15 The present invention also covers novel intermediates that are useful to prepare the compounds of the present invention. For example, the present invention covers novel alcohol precursors for the compounds. By way of further example, the present invention covers bis protected precursors for the compounds. Examples of each of these precursors are presented herein. The present invention also encompasses a process
20 comprising each or both of those precursors for the synthesis of the compounds of the present invention.

Two preferred compounds are compounds of the formulae



and



25

SOME ADVANTAGES

One key advantage of the present invention is that the sulphamate compounds of the present invention can act as STS inhibitors.

30

Another advantage of the compounds of the present invention is that they may be potent *in vivo*.

Some of the compounds of the present invention may be non-oestrogenic compounds.

5 Here, the term "non-oestrogenic" means exhibiting no or substantially no oestrogenic activity.

Another advantage is that some of the compounds may not be capable of being metabolised to compounds which display or induce hormonal activity.

10

Some of the compounds of the present invention are also advantageous in that they may be orally active.

Some of the compounds of the present invention may useful for the treatment of cancer, such as breast cancer, as well as (or in the alternative) non-malignant conditions, such as the prevention of auto-immune diseases, particularly when pharmaceuticals may need to be administered from an early age.

15

Thus, some of the compounds of the present invention are also believed to have therapeutic uses other than for the treatment of endocrine-dependent cancers, such as the treatment of autoimmune diseases.

20

The compounds of the present invention may also be useful as an inducer of apoptosis.

25 The compounds of the present invention may also be useful as a cell growth inhibitors.

STEROID SULPHATASE

Steroid sulphatase – which is sometimes referred to as steroid sulfatase or steryl sulphatase or "STS" for short – hydrolyses several sulphated steroids, such as oestrone sulphate, dehydroepiandrosterone sulphate and cholesterol sulphate. STS has been allocated the enzyme number EC 3.1.6.2.

30

STS has been cloned and expressed. For example see Stein *et al* (J. Biol. Chem. 264:13865-13872 (1989)) and Yen *et al* (Cell 49:443-454(1987)).

35

STS is an enzyme that has been implicated in a number of disease conditions.

By way of example, workers have found that a total deficiency in STS produces
5 ichthyosis. According to some workers, STS deficiency is fairly prevalent in Japan. The
same workers (Sakura *et al*, J Inherit Metab Dis 1997 Nov;20(6):807-10) have also
reported that allergic diseases – such as bronchial asthma, allergic rhinitis, or atopic
dermatitis - may be associated with a steroid sulphatase deficiency.

10 In addition to disease states being brought on through a total lack of STS activity, an
increased level of STS activity may also bring about disease conditions. By way of
example, and as indicated above, there is strong evidence to support a role of STS in
breast cancer growth and metastasis.

15 STS has also been implicated in other disease conditions. By way of example, Le Roy
et al (Behav Genet 1999 Mar;29(2):131-6) have determined that there may be a genetic
correlation between steroid sulphatase concentration and initiation of attack behaviour in
mice. The authors conclude that sulphatation of steroids may be the prime mover of a
complex network, including genes shown to be implicated in aggression by
20 mutagenesis.

STS INHIBITION

It is believed that some disease conditions associated with STS activity are due to
25 conversion of a nonactive, sulphated oestrone to an active, nonsulphated oestrone. In
disease conditions associated with STS activity, it would be desirable to inhibit STS
activity.

Here, the term "inhibit" includes reduce and/or eliminate and/or mask and/or prevent the
30 detrimental action of STS.

STS INHIBITOR

In accordance with the present invention, the compound of the present invention is
35 capable of acting as an STS inhibitor.

Here, the term "inhibitor" as used herein with respect to the compound of the present invention means a compound that can inhibit STS activity – such as reduce and/or eliminate and/or mask and/or prevent the detrimental action of STS. The STS inhibitor
5 may act as an antagonist.

The ability of compounds to inhibit oestrone sulphatase activity can be assessed using either intact MCF-7 breast cancer cells or placental microsomes. In addition, an animal model may be used. Details on suitable Assay Protocols are presented in following
10 sections. It is to be noted that other assays could be used to determine STS activity and thus STS inhibition. For example, reference may also be made to the teachings of WO-A-99/50453.

Preferably, for some applications, the compound is further characterised by the feature
15 that if the sulphamate group were to be substituted by a sulphate group to form a sulphate derivative, then the sulphate derivative would be hydrolysable by an enzyme having steroid sulphatase (E.C. 3.1.6.2) activity - i.e. when incubated with steroid sulphatase EC 3.1.6.2 at pH 7.4 and 37°C.

In one preferred embodiment, if the sulphamate group of the compound were to be replaced with a sulphate group to form a sulphate compound then that sulphate compound would be hydrolysable by an enzyme having steroid sulphatase (E.C. 3.1.6.2) activity and would yield a Km value of less than 200 mmolar, preferably less than 150 mmolar, preferably less than 100 mmolar, preferably less than 75 mmolar,
20 preferably less than 50 mmolar, when incubated with steroid sulphatase EC 3.1.6.2 at pH 7.4 and 37°C.
25

In a preferred embodiment, the compound of the present invention is not hydrolysable by an enzyme having steroid sulphatase (E.C. 3.1.6.2) activity.
30

For some applications, preferably the compound of the present invention has at least about a 100 fold selectivity to a desired target (e.g. STS), preferably at least about a 150 fold selectivity to the desired target, preferably at least about a 200 fold selectivity to the desired target, preferably at least about a 250 fold selectivity to the desired target,
35 preferably at least about a 300 fold selectivity to the desired target, preferably at least

about a 350 fold selectivity to the desired target.

It is to be noted that the compound of the present invention may have other beneficial properties in addition to or in the alternative to its ability to inhibit STS activity.

5

GROUPS R¹ AND R²

As discussed above R¹ is an optional group of the formula -L¹-S-R^{1'}, and R² is an optional group of the formula -L²-S-R^{2'}. L¹ is an optional linker group. R^{1'} is a hydrocarbyl group. L² is an optional linker group. R^{2'} is a hydrocarbyl group.

10

Independently either of linker groups L¹ and L² may or may not be present. If present L¹ or L² may be a hydrocarbyl group.

Preferably L¹ and L² are independently selected from C₁-C₁₀ hydrocarbyl, C₁-C₅ hydrocarbyl or C₁-C₃ hydrocarbyl.

15

Preferably L¹ and L² are independently selected from hydrocarbon groups, preferably C₁-C₁₀ hydrocarbon, C₁-C₅ hydrocarbon or C₁-C₃ hydrocarbon.

20

Preferably L¹ and L² are independently selected from alkyl groups, C₁-C₁₀ alkyl, C₁-C₅ alkyl or C₁-C₃ alkyl.

The hydrocarbyl/hydrocarbon/alkyl of L¹ and L² may be straight chain or branched and/or may be saturated or unsaturated.

25

In one aspect L¹ and/or L² may contain a terminal sulphur moiety. In this aspect L¹ and/or L² are linked to the remainder of R¹ or R², respectively, by a sulphide bond and R¹ or R² as a whole contains a disulphide bond.

30

For the avoidance of doubt, S represents sulphur.

R^{1'} or R^{2'} are independently of each other a hydrocarbyl group.

Preferably R^{1'} and R^{2'} are independently selected from C₁-C₁₀ hydrocarbyl, C₁-C₅

35

hydrocarbyl or C₁-C₃ hydrocarbyl.

Preferably R^{1'} and R^{2'} are independently selected from hydrocarbon groups, C₁-C₁₀ hydrocarbon, C₁-C₅ hydrocarbon or C₁-C₃ hydrocarbon.

5

Preferably R^{1'} and R^{2'} are independently selected from alkyl groups, C₁-C₁₀ alkyl, C₁-C₅ alkyl or C₁-C₃ alkyl.

10 The hydrocarbyl/hydrocarbon/alkyl of R^{1'} and R^{2'} may be straight chain or branched and/or may be saturated or unsaturated.

in a highly preferred aspect R^{1'} and R^{2'} are independently selected from methyl (-CH₃) and ethyl (-CH₂CH₃).

15 GROUP K

Group K need not be a cyclic structure. In this regard, group K may be a linear structure that may have the ability to conform to a ring like structure when in *in vivo*.

20 In a preferred aspect, group K is cyclic - so as to form the cyclic group K.

Cyclic group K need not necessarily be fused to ring X. In this regard, they may be separated by a suitable spacer group - which may be a hydrocarbyl group.

25 In a preferred aspect, cyclic group K is fused to ring X.

Group K may be a polycyclic group, which need not be a fused polycycle.

30 Thus, in a preferred aspect, group K and ring X make up a polycyclic compound. As indicated, here the term "polycyclic" includes fused and non-fused ring structures including combinations thereof.

At least one of the cyclic groups K and X may be a heterocyclic group (a heterocycle) or a non-heterocyclic group.

35

At least one of the cyclic groups K and X may be a saturated ring structure or an unsaturated ring structure (such as an aryl group).

Preferably, at least one of the cyclic groups is an aryl ring.

5

If the cyclic group is polycyclic some or all of the ring components of the compound may be fused together or joined *via* one or more suitable spacer groups.

The polycyclic compound may comprise a number of fused rings. In this aspect the fused
10 rings may comprise any combination of different size rings, such as 3 six-membered rings (6,6,6), a six-membered ring, a seven-membered ring and a six-membered ring (6,7,6), a six-membered ring and two eight-membered rings (6,8,8) etc.

In one aspect the present invention relates to compounds wherein the polycyclic
15 compounds are other than (6,6,7) rings. In a further aspect, the present invention relates to compounds wherein the polycyclic compounds only contain rings having other than 7 members.

Preferably the polycyclic compound will contain, inclusive of all substituents, no more than
20 50 about carbon atoms, more usually no more than about 30 to 40 carbon atoms.

The polycyclic compound can comprise at least two ring components, or at least three ring components, or at least four ring components.

25 Preferably, the polycyclic compound comprises four ring components.

Preferred polycyclic compounds have a steroidal ring component, or bio-isosteres thereof.

HYDROCARBYL

30

The term "hydrocarbyl group" as used herein means a group comprising at least C and H and may optionally comprise one or more other suitable substituents. Examples of such substituents may include halo, alkoxy, nitro, an alkyl group, a cyclic group etc. In addition to the possibility of the substituents being a cyclic group, a combination of
35 substituents may form a cyclic group. If the hydrocarbyl group comprises more than one

C then those carbons need not necessarily be linked to each other. For example, at least two of the carbons may be linked via a suitable element or group. Thus, the hydrocarbyl group may contain hetero atoms. Suitable hetero atoms will be apparent to those skilled in the art and include, for instance, sulphur, nitrogen and oxygen. A non-limiting example of a hydrocarbyl group is an acyl group.

A typical hydrocarbyl group is a hydrocarbon group. Here the term "hydrocarbon" means any one of an alkyl group, an alkenyl group, an alkynyl group, which groups may be linear, branched or cyclic, or an aryl group. The term hydrocarbon also includes those groups but wherein they have been optionally substituted. If the hydrocarbon is a branched structure having substituent(s) thereon, then the substitution may be on either the hydrocarbon backbone or on the branch; alternatively the substitutions may be on the hydrocarbon backbone and on the branch.

15 SULPHAMATE GROUP

In one embodiment, the ring X has a sulphamate group as a substituent. The term "sulphamate" as used herein includes an ester of sulphamic acid, or an ester of an N-substituted derivative of sulphamic acid, or a salt thereof.

If R^3 is a sulphamate group then the compound of the present invention is referred to as a sulphamate compound.

Typically, the sulphamate group has the formula:



wherein preferably R^4 and R^5 are independently selected from H, alkyl, cycloalkyl, alkenyl and aryl, or combinations thereof, or together represent alkylene, wherein the or each alkyl or cycloalkyl or alkenyl or optionally contain one or more hetero atoms or groups.

When substituted, the N-substituted compounds of this invention may contain one or two N-alkyl, N-alkenyl, N-cycloalkyl or N-aryl substituents, preferably containing or each containing a maximum of 10 carbon atoms. When R^4 and/or R^5 is alkyl, the preferred

- values are those where R^4 and R^5 are each independently selected from lower alkyl groups containing from 1 to 6 carbon atoms, that is to say methyl, ethyl, propyl etc. R^4 and R^5 may both be methyl. When R^4 and/or R^5 is aryl, typical values are phenyl and tolyl (PhCH_3 ; o). Where R^4 and R^5 represent cycloalkyl, typical values are cyclopropyl, cyclopentyl, cyclohexyl etc. When joined together R^4 and R^5 typically represent an alkylene group providing a chain of 4 to 6 carbon atoms, optionally interrupted by one or more hetero atoms or groups, e.g. to provide a 5 membered heterocycle, e.g. morpholino, pyrrolidino or piperidino.
- 10 Within the values alkyl, cycloalkyl, alkenyl and aryl substituted groups are included containing as substituents therein one or more groups which do not interfere with the sulphatase inhibitory activity of the compound in question. Exemplary non-interfering substituents include hydroxy, amino, halo, alkoxy, alkyl and aryl.
- 15 In some embodiments, the sulphamate group may form a ring structure by being fused to (or associated with) one or more atoms in or on group X.

In some embodiments, there may be more than one sulphamate group. By way of example, there may be two sulphamates (i.e. bis-sulphamate compounds). If these compounds are based on a steroidal nucleus, preferably the second (or at least one of the additional) sulphamate group is located at position 17 of the steroidal nucleus. These groups need not be the same.

20

In some preferred embodiments, at least one of R^4 and R^5 is H.

25

In some further preferred embodiments, each of R^4 and R^5 is H.

PHOSPHONATE GROUP

- 30 If R^3 is a phosphonate group then the compound of the present invention is referred to as a phosphonate compound.

Typically, the phosphonate group has the formula:



wherein preferably R^6 is H, alkyl, cycloalkyl, alkenyl or aryl, or combinations thereof, wherein the or each alkyl or cycloalkyl or alkenyl or optionally contain one or more hetero atoms or groups.

5

When substituted, the N-substituted compounds of this invention may contain one or two N-alkyl, N-alkenyl, N-cycloalkyl or N-aryl substituents, preferably containing or each containing a maximum of 10 carbon atoms. When R^6 is alkyl, R^6 may be a lower alkyl groups containing from 1 to 6 carbon atoms, that is to say methyl, ethyl, propyl etc. By way of example, R^6 may be methyl. When R^6 is aryl, typical values are phenyl and tolyl ($\text{PhCH}_3; \text{o}$). Where R^6 represents cycloalkyl, typical values are cyclopropyl, cyclopentyl, cyclohexyl etc. R^6 may even comprise an alkylene group providing a chain of 4 to 6 carbon atoms, optionally interrupted by one or more hetero atoms or groups, e.g. to provide a 5 membered heterocycle, e.g. morpholino, pyrrolidino or piperidino.

15

Within the values alkyl, cycloalkyl, alkenyl and aryl substituted groups are included containing as substituents therein one or more groups which do not interfere with the sulphatase inhibitory activity of the compound in question. Exemplary non-interfering substituents include hydroxy, amino, halo, alkoxy, alkyl and aryl.

20


In some embodiments, the phosphonate group may form a ring structure by being fused to (or associated with) one or more atoms in or on group X.

In some embodiments, there may be more than one phosphonate group. By way of example, there may be two phosphonates (i.e. bis-phosphonate compounds). If these compounds are based on a steroidal nucleus, preferably the second (or at least one of the additional) phosphonate group is located at position 17 of the steroidal nucleus. These groups need not be the same.

30 THIOPHOSPHONATE GROUP

If R^3 is a thiophosphonate group then the compound of the present invention is referred to as a thiophosphonate compound.

35 Typically, the thiophosphonate group has the formula:



wherein preferably R^7 is H, alkyl, cycloalkyl, alkenyl or aryl, or combinations thereof,
5 wherein the or each alkyl or cycloalkyl or alkenyl or optionally contain one or more hetero atoms or groups.

When substituted, the N-substituted compounds of this invention may contain one or two N-alkyl, N-alkenyl, N-cycloalkyl or N-aryl substituents, preferably containing or each
10 containing a maximum of 10 carbon atoms. When R^7 is alkyl, R^7 may be a lower alkyl groups containing from 1 to 6 carbon atoms, that is to say methyl, ethyl, propyl etc. By way of example, R^7 may be methyl. When R^7 is aryl, typical values are phenyl and tolyl ($PhCH_3$;o). Where R^7 represents cycloalkyl, typical values are cyclopropyl, cyclopentyl, cyclohexyl etc. R^7 may even comprise an alkylene group providing a chain of 4 to 6
15 carbon atoms, optionally interrupted by one or more hetero atoms or groups, e.g. to provide a 5 membered heterocycle, e.g. morpholino, pyrrolidino or piperidino.

Within the values alkyl, cycloalkyl, alkenyl and aryl substituted groups are included containing as substituents therein one or more groups which do not interfere with the
20 sulphatase inhibitory activity of the compound in question. Exemplary non-interfering substituents include hydroxy, amino, halo, alkoxy, alkyl and aryl.

In some embodiments, the thiophosphonate group may form a ring structure by being fused to (or associated with) one or more atoms in or on group X.


25

In some embodiments, there may be more than one thiophosphonate group. By way of example, there may be two thiophosphonates (i.e. bis-thiophosphonate compounds). If these compounds are based on a steroidal nucleus, preferably the second (or at least one of the additional) thiophosphonate group is located at position 17 of the steroidal
30 nucleus. These groups need not be the same.

SULPHONATE GROUP

If R^3 is a sulphonate group then the compound of the present invention is referred to as
35 a sulphonate compound.

Typically, the sulphonate group has the formula:



5

wherein preferably R^8 is H, alkyl, cycloalkyl, alkenyl or aryl, or combinations thereof, wherein the or each alkyl or cycloalkyl or alkenyl or optionally contain one or more hetero atoms or groups.

- 10 When substituted, the N-substituted compounds of this invention may contain one or two N-alkyl, N-alkenyl, N-cycloalkyl or N-aryl substituents, preferably containing or each containing a maximum of 10 carbon atoms. When R^8 is alkyl, R^8 may be a lower alkyl groups containing from 1 to 6 carbon atoms, that is to say methyl, ethyl, propyl etc. By way of example, R^8 may be methyl. When R^8 is aryl, typical values are phenyl and tolyl
- 15 ($PhCH_3; o$). Where R^8 represents cycloalkyl, typical values are cyclopropyl, cyclopentyl, cyclohexyl etc. R^8 may even comprise an alkylene group providing a chain of 4 to 6 carbon atoms, optionally interrupted by one or more hetero atoms or groups, e.g. to provide a 5 membered heterocycle, e.g. morpholino, pyrrolidino or piperidino.
- 20 Within the values alkyl, cycloalkyl, alkenyl and aryl substituted groups are included containing as substituents therein one or more groups which do not interfere with the sulphonate inhibitory activity of the compound in question. Exemplary non-interfering substituents include hydroxy, amino, halo, alkoxy, alkyl and aryl.
- 25 In some embodiments, the sulphonate group may form a ring structure by being fused to (or associated with) one or more atoms in or on group X.

- In some embodiments, there may be more than one sulphonate group. By way of example, there may be two sulphonates (i.e. bis- sulphonate compounds). If these
- 30 compounds are based on a steroidal nucleus, preferably the second (or at least one of the additional) sulphonate group is located at position 17 of the steroidal nucleus. These groups need not be the same.

COMBINATION OF
SULPHONATE/PHOSPHONATE/THIOPHOSPHONATE/SULPHAMATE

For some compounds of the present invention there may be present one of a sulphonate as herein defined or a phosphonate as herein defined or a thiophosphonate as herein defined or a sulphamate as herein defined; and another of a sulphonate as herein defined or a phosphonate as herein defined or a thiophosphonate as herein defined or a sulphamate as herein defined. By way of example, the compound of the present invention may comprise one sulphamate group and one phosphonate group.

If these compounds of the present invention are based on a steroidal nucleus, preferably the other of said groups is located at position 17 of the steroidal nucleus.

MIMIC

In one aspect, X and K can be a mimic of a steroidal ring structure


The term "mimic" as used herein means having a similar or different structure but having a similar functional effect. In other words, group K and ring X together may be a bio-isostere of the rings of a steroid, or an active part thereof.

In a preferred aspect, group K and ring X together may be a bio-isostere of the rings of oestrone, or a part thereof.

STEROIDAL RING STRUCTURE

In one preferred aspect, X and K make up a steroidal ring structure - that is to say a cyclopentanophenanthrene skeleton, or bio-isosteres thereof.


As it is well known in the art, a classical steroidal ring structure has the generic formula of:



In the above formula, the rings have been labelled in the conventional manner.

An example of a bio-isostere is when any one or more of rings A, B, C and D is a heterocyclic ring and/or when any one or more of rings A, B, C and D has been substituted and/or when any one or more of rings A, B, C and D has been modified; but wherein the bio-isostere in the absence of the sulphamate group has steroidal properties.

In this regard, the structure of a preferred polycyclic structure can be presented as:



10

wherein each ring A', B', C' and D' independently represents a heterocyclic ring or a non-heterocyclic ring, which rings may be independently substituted or unsubstituted, saturated or unsaturated.

15

By way of example, any one or more of rings A', B', C' and D' may be independently substituted with suitable groups - such as an alkyl group, an aryl group, a hydroxy group, a halo group, a hydrocarbyl group, an oxyhydrocarbyl group etc.

20 An example of D' is a five or six membered non-heterocyclic ring having at least one substituent.

In one preferred embodiment, the ring D' is substituted with a ethinyl group.

25 If any one of rings A', B', C' and D' is a heterocyclic ring, then preferably that heterocyclic ring comprises a combination of C atoms and at least one N atom and/or at least one O atom. Other heterocyclic atoms may be present in the ring.

30 Examples of suitable, preferred steroidal nuclei rings A'-D' of the compounds of the present invention include rings A-D of dehydroepiandrosterone and oestrogens including oestrone.

Preferred steroidal nuclei rings A'-D' of the compounds of the present invention include rings A-D of:

oestrones and substituted oestrones, viz:

- 5 oestrone
- 2-OH-oestrone
- 4-OH-oestrone
- 6 α -OH-oestrone
- 7 α -OH-oestrone
- 10 16 α -OH-oestrone
- 16 β -OH-oestrone
- 2-MeO-oestrone
- 17-deoxyoestrone

15 oestradiols and substituted oestradiols, viz:

- 4-OH-17 β -oestradiol
- 6 α -OH-17 β -oestradiol
- 7 α -OH-17 β -oestradiol
- 4-OH-17 α -oestradiol
- 20 6 α -OH-17 α -oestradiol
- 7 α -OH-17 α -oestradiol
- 16 α -OH-17 α -oestradiol
- 16 α -OH-17 β -oestradiol
- 16 β -OH-17 α -oestradiol
- 25 16 β -OH-17 β -oestradiol
- 17 α -oestradiol
- 17 β -oestradiol
- 17 α -ethinyl-17 β -oestradiol
- 17 β -ethinyl-17 α -oestradiol
- 30 17-deoxyoestradiol

oestriols and substituted oestriols, viz:

- oestriol
- 4-OH-oestriol

6 α -OH-oestriol

7 α -OH-oestriol

17-deoxyoestriol

5 dehydroepiandrosterones and substituted dehydroepiandrosterones, viz:

dehydroepiandrosterones

6 α -OH-dehydroepiandrosterone

7 α -OH-dehydroepiandrosterone

16 α -OH-dehydroepiandrosterone

10 16 β -OH-dehydroepiandrosterone
androstenediol

In general terms the ring system A'B'C'D' may contain a variety of non-interfering substituents. In particular, the ring system A'B'C'D' may contain one or more hydroxy,
15 alkyl especially lower (C₁-C₆) alkyl, e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, n-pentyl and other pentyl isomers, and n-hexyl and other hexyl isomers, alkoxy especially lower (C₁-C₆) alkoxy, e.g. methoxy, ethoxy, propoxy etc., alkynyl, e.g. ethynyl, or halogen, e.g. fluoro substituents.

20 NON-STEROID STRUCTURES

In an alternative embodiment, the compound of the present invention may not contain or be based on a steroid nucleus. In this regard, the polycyclic compound may contain or be based on a non-steroidal ring system - such as diethylstilboestrol, stilboestrol, coumarins,
25 flavonoids, combrestatin and other ring systems. Other suitable non-steroidal compounds for use in or as the composition of the present invention may be found in US-A-5567831.

OTHER SUBSTITUENTS

30 The compound of the present invention may have substituents other than R¹, R² and R³. By way of example, these other substituents may be one or more of: one or more sulphamate group(s), one or more phosphonate group(s), one or more thiophosphonate group(s), one or more sulphonate group(s), one or more sulphonamide group(s), one or more halo groups, one or more O groups, one or more hydroxy groups, one or more
35 amino groups, one or more sulphur containing group(s), one or more hydrocarbyl

group(s) – such as an oxyhydrocarbyl group.

OXYHYDROCARBYL

5 The term "oxyhydrocarbyl" group as used herein means a group comprising at least C, H and O and may optionally comprise one or more other suitable substituents. Examples of such substituents may include halo-, alkoxy-, nitro-, an alkyl group, a cyclic group etc. In addition to the possibility of the substituents being a cyclic group, a combination of substituents may form a cyclic group. If the oxyhydrocarbyl group comprises more than
10 one C then those carbons need not necessarily be linked to each other. For example, at least two of the carbons may be linked *via* a suitable element or group. Thus, the oxyhydrocarbyl group may contain hetero atoms. Suitable hetero atoms will be apparent to those skilled in the art and include, for instance, sulphur and nitrogen.

15 In one embodiment of the present invention, the oxyhydrocarbyl group is a oxyhydrocarbon group.

Here the term "oxyhydrocarbon" means any one of an alkoxy group, an oxyalkenyl group, an oxyalkynyl group, which groups may be linear, branched or cyclic, or an
20 oxyaryl group. The term oxyhydrocarbon also includes those groups but wherein they have been optionally substituted. If the oxyhydrocarbon is a branched structure having substituent(s) thereon, then the substitution may be on either the hydrocarbon backbone or on the branch; alternatively the substitutions may be on the hydrocarbon backbone and on the branch.

25

Typically, the oxyhydrocarbyl group is of the formula $C_{1-6}O$ (such as a $C_{1-3}O$).

ASSAY FOR DETERMINING STS ACTIVITY USING CANCER CELLS

(PROTOCOL 1)

30

Inhibition of Steroid Sulphatase Activity in MCF-7 cells

Steroid sulphatase activity is measured *in vitro* using intact MCF-7 human breast cancer cells. This hormone dependent cell line is widely used to study the control of human
35 breast cancer cell growth. It possesses significant steroid sulphatase activity (MacIndoe

et al. *Endocrinology*, 123, 1281-1287 (1988); Purohit & Reed, *Int. J. Cancer*, 50, 901-905 (1992)) and is available in the U.S.A. from the American Type Culture Collection (ATCC) and in the U.K. (e.g. from The Imperial Cancer Research Fund).

- 5 Cells are maintained in Minimal Essential Medium (MEM) (Flow Laboratories, Irvine, Scotland) containing 20 mM HEPES, 5% foetal bovine serum, 2 mM glutamine, non-essential amino acids and 0.075% sodium bicarbonate. Up to 30 replicate 25 cm² tissue culture flasks are seeded with approximately 1×10^5 cells/flask using the above medium. Cells are grown to 80% confluency and the medium is changed every third
10 day.

- Intact monolayers of MCF-7 cells in triplicate 25 cm² tissue culture flasks are washed with Earle's Balanced Salt Solution (EBSS from ICN Flow, High Wycombe, U.K.) and incubated for 3-4 hours at 37°C with 5 pmol (7×10^5 dpm) [6,7-³H]oestrone-3-sulphate
15 (specific activity 60 Ci/mmol from New England Nuclear, Boston, Mass., U.S.A.) in serum-free MEM (2.5 ml) together with oestrone-3-sulphamate (11 concentrations: 0; 1fM; 0.01pM; 0.1pM; 1pM; 0.01nM; 0.1nM; 1nM; 0.01mM; 0.1mM; 1mM). After incubation each flask is cooled and the medium (1 ml) is pipetted into separate tubes containing [¹⁴C]oestrone (7×10^3 dpm) (specific activity 97 Ci/mmol from Amersham
20 International Radiochemical Centre, Amersham, U.K.). The mixture is shaken thoroughly for 30 seconds with toluene (5 ml). Experiments have shown that >90% [¹⁴C] oestrone and <0.1% [³H]oestrone-3-sulphate is removed from the aqueous phase by this treatment. A portion (2 ml) of the organic phase is removed, evaporated and the ³H and ¹⁴C content of the residue determined by scintillation spectrometry. The mass of
25 oestrone-3-sulphate hydrolysed was calculated from the ³H counts obtained (corrected for the volumes of the medium and organic phase used, and for recovery of [¹⁴C] oestrone added) and the specific activity of the substrate. Each batch of experiments includes incubations of microsomes prepared from a sulphatase-positive human placenta (positive control) and flasks without cells (to assess apparent non-enzymatic
30 hydrolysis of the substrate). The number of cell nuclei per flask is determined using a Coulter Counter after treating the cell monolayers with Zaponin. One flask in each batch is used to assess cell membrane status and viability using the Trypan Blue exclusion method (Phillips, H.J. (1973) In: *Tissue culture and applications*, [eds: Kruse, D.F. & Patterson, M.K.]; pp. 406-408; Academic Press, New York).

Results for steroid sulphatase activity are expressed as the mean \pm 1 S.D. of the total product (oestrone + oestradiol) formed during the incubation period (20 hours) calculated for 106 cells and, for values showing statistical significance, as a percentage reduction (inhibition) over incubations containing no oestrone-3-sulphamate. Unpaired Student's t-test was used to test the statistical significance of results.

ASSAY FOR DETERMINING STS ACTIVITY USING PLACENTAL MICROSOMES
(PROTOCOL 2)

10 Inhibition of Steroid Sulphatase Activity in Placental Microsomes

Sulphatase-positive human placenta from normal term pregnancies are thoroughly minced with scissors and washed once with cold phosphate buffer (pH 7.4, 50 mM) then re-suspended in cold phosphate buffer (5 ml/g tissue). Homogenisation is accomplished with an Ultra-Turrax homogeniser, using three 10 second bursts separated by 2 minute cooling periods in ice. Nuclei and cell debris are removed by centrifuging (4°C) at 2000g for 30 minutes and portions (2 ml) of the supernatant are stored at 20°C. The protein concentration of the supernatants is determined by the method of Bradford (Anal. Biochem., 72, 248-254 (1976)).

20

Incubations (1 ml) are carried out using a protein concentration of 100 mg/ml, substrate concentration of 20 mM [6,7-3H]oestrone-3-sulphate (specific activity 60 Ci/mmol from New England Nuclear, Boston, Mass., U.S.A.) and an incubation time of 20 minutes at 37°C. If necessary eight concentrations of compounds are employed: 0 (i.e. control); 0.05mM; 0.1mM; 0.2mM; 0.4mM; 0.6mM; 0.8mM; 1.0mM. After incubation each sample is cooled and the medium (1 ml) was pipetted into separate tubes containing [14C]oestrone (7 x 10³ dpm) (specific activity 97 Ci/mmol from Amersham International Radiochemical Centre, Amersham, U.K.). The mixture is shaken thoroughly for 30 seconds with toluene (5 ml). Experiments have shown that >90% [14C]oestrone and <0.1% [3H]oestrone-3-sulphate is removed from the aqueous phase by this treatment. A portion (2 ml) of the organic phase was removed, evaporated and the 3H and 14C content of the residue determined by scintillation spectrometry. The mass of oestrone-3-sulphate hydrolysed is calculated from the 3H counts obtained (corrected for the volumes of the medium and organic phase used, and for recovery of [14C]oestrone added) and the specific activity of the substrate.

ANIMAL ASSAY MODEL FOR DETERMINING STS ACTIVITY
(PROTOCOL 3)

Inhibition of oestrone sulphatase activity *in vivo*

5

The compounds of the present invention may be studied using an animal model, in particular in ovariectomised rats. In this model compounds which are oestrogenic stimulate uterine growth.

- 10 The compound (0.1 mg/Kg/day for five days) is administered orally to rats with another group of animals receiving vehicle only (propylene glycol). At the end of the study samples of liver tissue were obtained and oestrone sulphatase activity assayed using 3H oestrone sulphate as the substrate as previously described (see PCT/GB95/02638).

15 ANIMAL ASSAY MODEL FOR DETERMINING OESTROGENIC ACTIVITY
(PROTOCOL 4)

Lack of *in vivo* oestrogenicity

- 20 The compounds of the present invention may be studied using an animal model, in particular in ovariectomised rats. In this model, compounds which are oestrogenic stimulate uterine growth.

25 The compound (0.1 mg/Kg/day for five days) was administered orally to rats with another group of animals receiving vehicle only (propylene glycol). At the end of the study uteri were obtained and weighed with the results being expressed as uterine weight/whole body weight x 100.

Compounds having no significant effect on uterine growth are not oestrogenic.

30

BIOTECHNOLOGICAL ASSAYS FOR DETERMINING STS ACTIVITY
(PROTOCOL 5)

- 35 The ability of compounds to inhibit oestrone sulphatase activity can also be assessed using amino acid sequences or nucleotide sequences encoding STS, or active

fragments, derivatives, homologues or variants thereof in, for example, high-through put screens.

Any one or more of appropriate targets - such as an amino acid sequence and/or
5 nucleotide sequence - may be used for identifying an agent capable of modulating STS
in any of a variety of drug screening techniques. The target employed in such a test
may be free in solution, affixed to a solid support, borne on a cell surface, or located
intracellularly. The abolition of target activity or the formation of binding complexes
between the target and the agent being tested may be measured.

10

The assay of the present invention may be a screen, whereby a number of agents are
tested. In one aspect, the assay method of the present invention is a high through put
screen.

15 Techniques for drug screening may be based on the method described in Geysen,
European Patent Application 84/03564, published on September 13, 1984. In summary,
large numbers of different small peptide test compounds are synthesised on a solid
substrate, such as plastic pins or some other surface. The peptide test compounds are
reacted with a suitable target or fragment thereof and washed. Bound entities are then
20 detected - such as by appropriately adapting methods well known in the art. A purified
target can also be coated directly onto plates for use in a drug screening techniques.
Alternatively, non-neutralising antibodies can be used to capture the peptide and
immobilise it on a solid support.

25 This invention also contemplates the use of competitive drug screening assays in which
neutralising antibodies capable of binding a target specifically compete with a test
compound for binding to a target.

Another technique for screening provides for high throughput screening (HTS) of agents
30 having suitable binding affinity to the substances and is based upon the method
described in detail in WO 84/03564.

It is expected that the assay methods of the present invention will be suitable for both
small and large-scale screening of test compounds as well as in quantitative assays.

35

In one preferred aspect, the present invention relates to a method of identifying agents that selectively modulate STS, which compounds have the formula (Ia).

REPORTERS

5

A wide variety of reporters may be used in the assay methods (as well as screens) of the present invention with preferred reporters providing conveniently detectable signals (e.g. by spectroscopy). By way of example, a reporter gene may encode an enzyme which catalyses a reaction which alters light absorption properties.

10

Other protocols include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA) and fluorescent activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilising monoclonal antibodies reactive to two non-interfering epitopes may even be used. These and other assays are described, among
15 other places, in Hampton R et al (1990, Serological Methods, A Laboratory Manual, APS Press, St Paul MN) and Maddox DE et al (1983, J Exp Med 15 8:121 1).

Examples of reporter molecules include but are not limited to (β -galactosidase, invertase, green fluorescent protein, luciferase, chloramphenicol, acetyltransferase, (-
20 glucuronidase, exo-glucanase and glucoamylase. Alternatively, radiolabelled or fluorescent tag-labelled nucleotides can be incorporated into nascent transcripts which are then identified when bound to oligonucleotide probes.

By way of further examples, a number of companies such as Pharmacia Biotech
25 (Piscataway, NJ), Promega (Madison, WI), and US Biochemical Corp (Cleveland, OH) supply commercial kits and protocols for assay procedures. Suitable reporter molecules or labels include those radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents as well as substrates, cofactors, inhibitors, magnetic particles and the like. Patents teaching the use of such labels include US-A-3817837; US-A-
30 3850752; US-A-3939350; US-A-3996345; US-A-4277437; US-A-4275149 and US-A-4366241.

HOST CELLS

35 The term "host cell" - in relation to the present invention includes any cell that could

comprise the target for the agent of the present invention.

Thus, a further embodiment of the present invention provides host cells transformed or transfected with a polynucleotide that is or expresses the target of the present invention.

5 Preferably said polynucleotide is carried in a vector for the replication and expression of polynucleotides that are to be the target or are to express the target. The cells will be chosen to be compatible with the said vector and may for example be prokaryotic (for example bacterial), fungal, yeast or plant cells.

10 The gram negative bacterium *E. coli* is widely used as a host for heterologous gene expression. However, large amounts of heterologous protein tend to accumulate inside the cell. Subsequent purification of the desired protein from the bulk of *E.coli* intracellular proteins can sometimes be difficult.

15 In contrast to *E.coli*, bacteria from the genus *Bacillus* are very suitable as heterologous hosts because of their capability to secrete proteins into the culture medium. Other bacteria suitable as hosts are those from the genera *Streptomyces* and *Pseudomonas*.

Depending on the nature of the polynucleotide encoding the polypeptide of the present invention, and/or the desirability for further processing of the expressed protein,
20 eukaryotic hosts such as yeasts or other fungi may be preferred. In general, yeast cells are preferred over fungal cells because they are easier to manipulate. However, some proteins are either poorly secreted from the yeast cell, or in some cases are not processed properly (e.g. hyperglycosylation in yeast). In these instances, a different
25 fungal host organism should be selected.

Examples of suitable expression hosts within the scope of the present invention are fungi such as *Aspergillus* species (such as those described in EP-A-0184438 and EP-A-0284603) and *Trichoderma* species; bacteria such as *Bacillus* species (such as those
30 described in EP-A-0134048 and EP-A-0253455), *Streptomyces* species and *Pseudomonas* species; and yeasts such as *Kluyveromyces* species (such as those described in EP-A-0096430 and EP-A-0301670) and *Saccharomyces* species. By way of example, typical expression hosts may be selected from *Aspergillus niger*, *Aspergillus niger* var. *tubigenis*, *Aspergillus niger* var. *awamori*, *Aspergillus aculeatis*, *Aspergillus*
35 *nidulans*, *Aspergillus oryzae*, *Trichoderma reesei*, *Bacillus subtilis*, *Bacillus licheniformis*,

Bacillus amyloliquefaciens, *Kluyveromyces lactis* and *Saccharomyces cerevisiae*.

The use of suitable host cells - such as yeast, fungal and plant host cells - may provide for post-translational modifications (e.g. myristoylation, glycosylation, truncation, lapidation and tyrosine, serine or threonine phosphorylation) as may be needed to confer optimal biological activity on recombinant expression products of the present invention.

ORGANISM

10

The term "organism" in relation to the present invention includes any organism that could comprise the target according to the present invention and/or products obtained therefrom. Examples of organisms may include a fungus, yeast or a plant.

15 The term "transgenic organism" in relation to the present invention includes any organism that comprises the target according to the present invention and/or products obtained.

TRANSFORMATION OF HOST CELLS/HOST ORGANISMS

20

As indicated earlier, the host organism can be a prokaryotic or a eukaryotic organism. Examples of suitable prokaryotic hosts include *E. coli* and *Bacillus subtilis*. Teachings on the transformation of prokaryotic hosts is well documented in the art, for example see Sambrook *et al* (Molecular Cloning: A Laboratory Manual, 2nd edition, 1989, Cold Spring Harbor Laboratory Press) and Ausubel *et al.*, Current Protocols in Molecular Biology (1995), John Wiley & Sons, Inc.

If a prokaryotic host is used then the nucleotide sequence may need to be suitably modified before transformation - such as by removal of introns.

30

In another embodiment the transgenic organism can be a yeast. In this regard, yeast have also been widely used as a vehicle for heterologous gene expression. The species *Saccharomyces cerevisiae* has a long history of industrial use, including its use for heterologous gene expression. Expression of heterologous genes in *Saccharomyces cerevisiae* has been reviewed by Goodey *et al* (1987, Yeast

35

Biotechnology, D R Berry *et al*, eds, pp 401-429, Allen and Unwin, London) and by King *et al* (1989, Molecular and Cell Biology of Yeasts, E F Walton and G T Yarronton, eds, pp 107-133, Blackie, Glasgow).

- 5 For several reasons *Saccharomyces cerevisiae* is well suited for heterologous gene expression. First, it is non-pathogenic to humans and it is incapable of producing certain endotoxins. Second, it has a long history of safe use following centuries of commercial exploitation for various purposes. This has led to wide public acceptability. Third, the extensive commercial use and research devoted to the organism has resulted in a
10 wealth of knowledge about the genetics and physiology as well as large-scale fermentation characteristics of *Saccharomyces cerevisiae*.

A review of the principles of heterologous gene expression in *Saccharomyces cerevisiae* and secretion of gene products is given by E Hinchcliffe E Kenny (1993, "Yeast as a
15 vehicle for the expression of heterologous genes", Yeasts, Vol 5, Anthony H Rose and J Stuart Harrison, eds, 2nd edition, Academic Press Ltd.).

Several types of yeast vectors are available, including integrative vectors, which require recombination with the host genome for their maintenance, and autonomously
20 replicating plasmid vectors.

In order to prepare the transgenic *Saccharomyces*, expression constructs are prepared by inserting the nucleotide sequence into a construct designed for expression in yeast. Several types of constructs used for heterologous expression have been developed.
25 The constructs contain a promoter active in yeast fused to the nucleotide sequence, usually a promoter of yeast origin, such as the GAL1 promoter, is used. Usually a signal sequence of yeast origin, such as the sequence encoding the SUC2 signal peptide, is used. A terminator active in yeast ends the expression system.

30 For the transformation of yeast several transformation protocols have been developed. For example, a transgenic *Saccharomyces* according to the present invention can be prepared by following the teachings of Hinnen *et al* (1978, Proceedings of the National Academy of Sciences of the USA 75, 1929); Beggs, J D (1978, Nature, London, 275, 104); and Ito, H *et al* (1983, J Bacteriology 153, 163-168).

The transformed yeast cells are selected using various selective markers. Among the markers used for transformation are a number of auxotrophic markers such as LEU2, HIS4 and TRP1, and dominant antibiotic resistance markers such as aminoglycoside antibiotic markers, e.g. G418.

5

Another host organism is a plant. The basic principle in the construction of genetically modified plants is to insert genetic information in the plant genome so as to obtain a stable maintenance of the inserted genetic material. Several techniques exist for inserting the genetic information, the two main principles being direct introduction of the genetic information and introduction of the genetic information by use of a vector system. A review of the general techniques may be found in articles by Potrykus (Annu Rev Plant Physiol Plant Mol Biol [1991] 42:205-225) and Christou (Agro-Food-Industry Hi-Tech March/April 1994 17-27). Further teachings on plant transformation may be found in EP-A-0449375.

15

Thus, the present invention also provides a method of transforming a host cell with a nucleotide sequence that is to be the target or is to express the target. Host cells transformed with the nucleotide sequence may be cultured under conditions suitable for the expression of the encoded protein. The protein produced by a recombinant cell may be displayed on the surface of the cell. If desired, and as will be understood by those of skill in the art, expression vectors containing coding sequences can be designed with signal sequences which direct secretion of the coding sequences through a particular prokaryotic or eukaryotic cell membrane. Other recombinant constructions may join the coding sequence to nucleotide sequence encoding a polypeptide domain which will facilitate purification of soluble proteins (Kroll DJ et al (1993) DNA Cell Biol 12:441-53).

20

25

VARIANTS/HOMOLOGUES/DERIVATIVES

In addition to the specific amino acid sequences and nucleotide sequences mentioned herein, the present invention also encompasses the use of variants, homologue and derivatives thereof. Here, the term "homology" can be equated with "identity".

30

In the present context, an homologous sequence is taken to include an amino acid sequence which may be at least 75, 85 or 90% identical, preferably at least 95 or 98% identical. Although homology can also be considered in terms of similarity (i.e. amino

35

acid residues having similar chemical properties/functions), in the context of the present invention it is preferred to express homology in terms of sequence identity.

Homology comparisons can be conducted by eye, or more usually, with the aid of
5 readily available sequence comparison programs. These commercially available computer programs can calculate % homology between two or more sequences.

% homology may be calculated over contiguous sequences, i.e. one sequence is aligned with the other sequence and each amino acid in one sequence is directly
10 compared with the corresponding amino acid in the other sequence, one residue at a time. This is called an "ungapped" alignment. Typically, such ungapped alignments are performed only over a relatively short number of residues.

Although this is a very simple and consistent method, it fails to take into consideration
15 that, for example, in an otherwise identical pair of sequences, one insertion or deletion will cause the following amino acid residues to be put out of alignment, thus potentially resulting in a large reduction in % homology when a global alignment is performed. Consequently, most sequence comparison methods are designed to produce optimal alignments that take into consideration possible insertions and deletions without
20 penalising unduly the overall homology score. This is achieved by inserting "gaps" in the sequence alignment to try to maximise local homology.

However, these more complex methods assign "gap penalties" to each gap that occurs in the alignment so that, for the same number of identical amino acids, a sequence
25 alignment with as few gaps as possible - reflecting higher relatedness between the two compared sequences - will achieve a higher score than one with many gaps. "Affine gap costs" are typically used that charge a relatively high cost for the existence of a gap and a smaller penalty for each subsequent residue in the gap. This is the most commonly used gap scoring system. High gap penalties will of course produce
30 optimised alignments with fewer gaps. Most alignment programs allow the gap penalties to be modified. However, it is preferred to use the default values when using such software for sequence comparisons. For example when using the GCG Wisconsin Bestfit package (see below) the default gap penalty for amino acid sequences is -12 for a gap and -4 for each extension.

Calculation of maximum % homology therefore firstly requires the production of an optimal alignment, taking into consideration gap penalties. A suitable computer program for carrying out such an alignment is the GCG Wisconsin Bestfit package (University of Wisconsin, U.S.A.; Devereux et al., 1984, *Nucleic Acids Research* 12:387). Examples
5 of other software than can perform sequence comparisons include, but are not limited to, the BLAST package (see Ausubel et al., 1999 *ibid* – Chapter 18), FASTA (Atschul et al., 1990, *J. Mol. Biol.*, 403-410) and the GENEWORKS suite of comparison tools. Both BLAST and FASTA are available for offline and online searching (see Ausubel et al., 1999 *ibid*, pages 7-58 to 7-60). However it is preferred to use the GCG Bestfit program.

10 A further useful reference is that found in *FEMS Microbiol Lett* 1999 May 15;174(2):247-50 (and a published erratum appears in *FEMS Microbiol Lett* 1999 Aug 1;177(1):187-8).

Although the final % homology can be measured in terms of identity, the alignment
15 process itself is typically not based on an all-or-nothing pair comparison. Instead, a scaled similarity score matrix is generally used that assigns scores to each pairwise comparison based on chemical similarity or evolutionary distance. An example of such a matrix commonly used is the BLOSUM62 matrix - the default matrix for the BLAST suite of programs. GCG Wisconsin programs generally use either the public default
20 values or a custom symbol comparison table if supplied (see user manual for further details). It is preferred to use the public default values for the GCG package, or in the case of other software, the default matrix, such as BLOSUM62.

Once the software has produced an optimal alignment, it is possible to calculate %
25 homology, preferably % sequence identity. The software typically does this as part of the sequence comparison and generates a numerical result.

The sequences may also have deletions, insertions or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent
30 substance. Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues as long as the secondary binding activity of the substance is retained. For example, negatively charged amino acids include aspartic acid and glutamic acid; positively charged amino acids include lysine and arginine; and amino
35 acids with uncharged polar head groups having similar hydrophilicity values include

leucine, isoleucine, valine, glycine, alanine, asparagine, glutamine, serine, threonine, phenylalanine, and tyrosine.

Conservative substitutions may be made, for example according to the Table below.

- 5 Amino acids in the same block in the second column and preferably in the same line in the third column may be substituted for each other:

| | | |
|-----------|-------------------|---------|
| ALIPHATIC | Non-polar | G A P |
| | | I L V |
| | Polar – uncharged | C S T M |
| | | N Q |
| | Polar – charged | D E |
| | | K R |
| AROMATIC | | H F W Y |

EXPRESSION VECTORS

10

The nucleotide sequence for use as the target or for expressing the target can be incorporated into a recombinant replicable vector. The vector may be used to replicate and express the nucleotide sequence in and/or from a compatible host cell. Expression may be controlled using control sequences which include promoters/enhancers and other expression regulation signals. Prokaryotic promoters and promoters functional in eukaryotic cells may be used. Tissue specific or stimuli specific promoters may be used. Chimeric promoters may also be used comprising sequence elements from two or more different promoters described above.

15

- 20 The protein produced by a host recombinant cell by expression of the nucleotide sequence may be secreted or may be contained intracellularly depending on the sequence and/or the vector used. The coding sequences can be designed with signal sequences which direct secretion of the substance coding sequences through a particular prokaryotic or eukaryotic cell membrane.

25

FUSION PROTEINS

The target amino acid sequence may be produced as a fusion protein, for example to aid in extraction and purification. Examples of fusion protein partners include

- 30 glutathione-S-transferase (GST), 6xHis, GAL4 (DNA binding and/or transcriptional

activation domains) and (-galactosidase. It may also be convenient to include a proteolytic cleavage site between the fusion protein partner and the protein sequence of interest to allow removal of fusion protein sequences. Preferably the fusion protein will not hinder the activity of the target.

5

The fusion protein may comprise an antigen or an antigenic determinant fused to the substance of the present invention. In this embodiment, the fusion protein may be a non-naturally occurring fusion protein comprising a substance which may act as an adjuvant in the sense of providing a generalised stimulation of the immune system. The antigen or antigenic determinant may be attached to either the amino or carboxy terminus of the substance.

10

In another embodiment of the invention, the amino acid sequence may be ligated to a heterologous sequence to encode a fusion protein. For example, for screening of peptide libraries for agents capable of affecting the substance activity, it may be useful to encode a chimeric substance expressing a heterologous epitope that is recognised by a commercially available antibody.

15

THERAPY

20

The compounds of the present invention may be used as therapeutic agents – i.e. in therapy applications.

The term “therapy” includes curative effects, alleviation effects, and prophylactic effects.

25

The therapy may be on humans or animals, preferably female animals.

PHARMACEUTICAL COMPOSITIONS

In one aspect, the present invention provides a pharmaceutical composition, which comprises a compound according to the present invention and optionally a pharmaceutically acceptable carrier, diluent or excipient (including combinations thereof).

The pharmaceutical compositions may be for human or animal usage in human and

35

veterinary medicine and will typically comprise any one or more of a pharmaceutically acceptable diluent, carrier, or excipient. Acceptable carriers or diluents for therapeutic use are well known in the pharmaceutical art, and are described, for example, in Remington's *Pharmaceutical Sciences*, Mack Publishing Co. (A. R. Gennaro edit.
5 1985). The choice of pharmaceutical carrier, excipient or diluent can be selected with regard to the intended route of administration and standard pharmaceutical practice. The pharmaceutical compositions may comprise as - or in addition to - the carrier, excipient or diluent any suitable binder(s), lubricant(s), suspending agent(s), coating agent(s), solubilising agent(s).

10

Preservatives, stabilisers, dyes and even flavouring agents may be provided in the pharmaceutical composition. Examples of preservatives include sodium benzoate, sorbic acid and esters of p-hydroxybenzoic acid. Antioxidants and suspending agents may be also used.

15

There may be different composition/formulation requirements dependent on the different delivery systems. By way of example, the pharmaceutical composition of the present invention may be formulated to be delivered using a mini-pump or by a mucosal route, for example, as a nasal spray or aerosol for inhalation or ingestible solution, or
20 parenterally in which the composition is formulated by an injectable form, for delivery, by, for example, an intravenous, intramuscular or subcutaneous route. Alternatively, the formulation may be designed to be delivered by both routes.

Where the agent is to be delivered mucosally through the gastrointestinal mucosa, it
25 should be able to remain stable during transit through the gastrointestinal tract; for example, it should be resistant to proteolytic degradation, stable at acid pH and resistant to the detergent effects of bile.

Where appropriate, the pharmaceutical compositions can be administered by inhalation,
30 in the form of a suppository or pessary, topically in the form of a lotion, solution, cream, ointment or dusting powder, by use of a skin patch, orally in the form of tablets containing excipients such as starch or lactose, or in capsules or ovules either alone or in admixture with excipients, or in the form of elixirs, solutions or suspensions containing flavouring or colouring agents, or they can be injected parenterally, for example
35 intravenously, intramuscularly or subcutaneously. For parenteral administration, the

compositions may be best used in the form of a sterile aqueous solution which may contain other substances, for example enough salts or monosaccharides to make the solution isotonic with blood. For buccal or sublingual administration the compositions may be administered in the form of tablets or lozenges which can be formulated in a conventional manner.

COMBINATION PHARMACEUTICAL

The compound of the present invention may be used in combination with one or more other active agents, such as one or more other pharmaceutically active agents.

By way of example, the compounds of the present invention may be used in combination with other STS inhibitors and/or other inhibitors such as an aromatase inhibitor (such as for example, 4hydroxyandrostenedione (4-OHA)) and/or steroids – such as the naturally occurring sterneurosteroids dehydroepiandrosterone sulfate (DHEAS) and pregnenolone sulfate (PS) and/or other structurally similar organic compounds. Exaples of other STS inhibitors may be found in the above references. By way of example, STS inhibitors for use in the present invention include EMATE, and either or both of the 2-ethyl and 2-methoxy 17-deoxy compounds that are analogous to compound 5 presented herein.

In addition, or in the alternative, the compound of the present invention may be used in combination with a biological response modifier.

The term biological response modifier ("BRM") includes cytokines, immune modulators, growth factors, haematopoiesis regulating factors, colony stimulating factors, chemotactic, haemolytic and thrombolytic factors, cell surface receptors, ligands, leukocyte adhesion molecules, monoclonal antibodies, preventative and therapeutic vaccines, hormones, extracellular matrix components, fibronectin, etc. For some applications, preferably, the biological response modifier is a cytokine. Examples of cytokines include: interleukins (IL) - such as IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-19; Tumour Necrosis Factor (TNF) - such as TNF- α ; Interferon alpha, beta and gamma; TGF- β . For some applications, preferably the cytokine is tumour necrosis factor (TNF). For some applications, the TNF may be any type of TNF - such as TNF- α , TNF- β , including derivatives or mixtures thereof. More preferably the cytokine is TNF- α . Teachings on TNF may be found in the art - such as WO-A-98/08870

and WO-A-98/13348.

ADMINISTRATION

- 5 Typically, a physician will determine the actual dosage which will be most suitable for an individual subject and it will vary with the age, weight and response of the particular patient. The dosages below are exemplary of the average case. There can, of course, be individual instances where higher or lower dosage ranges are merited.
- 10 The compositions of the present invention may be administered by direct injection. The composition may be formulated for parenteral, mucosal, intramuscular, intravenous, subcutaneous, intraocular or transdermal administration. Depending upon the need, the agent may be administered at a dose of from 0.01 to 30 mg/kg body weight, such as from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight.
- 15 By way of further example, the agents of the present invention may be administered in accordance with a regimen of 1 to 4 times per day, preferably once or twice per day. The specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound
- 20 employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.
- 25 Aside from the typical modes of delivery – indicated above – the term “administered” also includes delivery by techniques such as lipid mediated transfection, liposomes, immunoliposomes, lipofectin, cationic facial amphiphiles (CFAs) and combinations thereof. The routes for such delivery mechanisms include but are not limited to mucosal, nasal, oral, parenteral, gastrointestinal, topical, or sublingual routes.
- 30 The term “administered” includes but is not limited to delivery by a mucosal route, for example, as a nasal spray or aerosol for inhalation or as an ingestible solution; a parenteral route where delivery is by an injectable form, such as, for example, an intravenous, intramuscular or subcutaneous route.
- 35 Thus, for pharmaceutical administration, the STS inhibitors of the present invention can

be formulated in any suitable manner utilising conventional pharmaceutical formulating techniques and pharmaceutical carriers, adjuvants, excipients, diluents etc. and usually for parenteral administration. Approximate effective dose rates may be in the range from 1 to 1000 mg/day, such as from 10 to 900 mg/day or even from 100 to 800 mg/day depending on the individual activities of the compounds in question and for a patient of average (70Kg) bodyweight. More usual dosage rates for the preferred and more active compounds will be in the range 200 to 800 mg/day, more preferably, 200 to 500 mg/day, most preferably from 200 to 250 mg/day. They may be given in single dose regimes, split dose regimes and/or in multiple dose regimes lasting over several days. For oral administration they may be formulated in tablets, capsules, solution or suspension containing from 100 to 500 mg of compound per unit dose. Alternatively and preferably the compounds will be formulated for parenteral administration in a suitable parenterally administrable carrier and providing single daily dosage rates in the range 200 to 800 mg, preferably 200 to 500, more preferably 200 to 250 mg. Such effective daily doses will, however, vary depending on inherent activity of the active ingredient and on the bodyweight of the patient, such variations being within the skill and judgement of the physician.

CELL CYCLING

The compounds of the present invention may be useful in the method of treatment of a cell cycling disorder.

As discussed in "Molecular Cell Biology" 3rd Ed. Lodish *et al.* pages 177-181 different eukaryotic cells can grow and divide at quite different rates. Yeast cells, for example, can divide every 120 min., and the first divisions of fertilised eggs in the embryonic cells of sea urchins and insects take only 1530 min. because one large pre-existing cell is subdivided. However, most growing plant and animal cells take 10-20 hours to double in number, and some duplicate at a much slower rate. Many cells in adults, such as nerve cells and striated muscle cells, do not divide at all; others, like the fibroblasts that assist in healing wounds, grow on demand but are otherwise quiescent.

Still, every eukaryotic cell that divides must be ready to donate equal genetic material to two daughter cells. DNA synthesis in eukaryotes does not occur throughout the cell division cycle but is restricted to a part of it before cell division.

The relationship between eukaryotic DNA synthesis and cell division has been thoroughly analysed in cultures of mammalian cells that were all capable of growth and division. In contrast to bacteria, it was found, eukaryotic cells spend only a part of their
5 time in DNA synthesis, and it is completed hours before cell division (mitosis). Thus a gap of time occurs after DNA synthesis and before cell division; another gap was found to occur after division and before the next round of DNA synthesis. This analysis led to the conclusion that the eukaryotic cell cycle consists of an M (mitotic) phase, a G_1 phase (the first gap), the S (DNA synthesis) phase, a G_2 phase (the second gap), and back to
10 M. The phases between mitoses (G_1 , S, and G_2) are known collectively as the interphase.

Many nondividing cells in tissues (for example, all quiescent fibroblasts) suspend the cycle after mitosis and just prior to DNA synthesis; such "resting" cells are said to have
15 exited from the cell cycle and to be in the G_0 state.

It is possible to identify cells when they are in one of the three interphase stages of the cell cycle, by using a fluorescence-activated cell sorter (FACS) to measure their relative DNA content: a cell that is in G_1 (before DNA synthesis) has a defined amount x of DNA;
20 during S (DNA replication), it has between x and $2x$; and when in G_2 (or M), it has $2x$ of DNA.

The stages of mitosis and cytokinesis in an animal cell are as follows

25 (a) Interphase. The G_2 stage of interphase immediately precedes the beginning of mitosis. Chromosomal DNA has been replicated and bound to protein during the S phase, but chromosomes are not yet seen as distinct structures. The nucleolus is the only nuclear substructure that is visible under light microscope. In a diploid cell before DNA replication there are two morphologic chromosomes of each type, and the cell is
30 said to be $2n$. In G_2 , after DNA replication, the cell is $4n$. There are four copies of each chromosomal DNA. Since the sister chromosomes have not yet separated from each other, they are called sister chromatids.

b) Early prophase. Centrioles, each with a newly formed daughter centriole, begin
35 moving toward opposite poles of the cell; the chromosomes can be seen as long

threads. The nuclear membrane begins to disaggregate into small vesicles.

(c) Middle and late prophase. Chromosome condensation is completed; each visible chromosome structure is composed of two chromatids held together at their centromeres. Each chromatid contains one of the two newly replicated daughter DNA molecules. The microtubular spindle begins to radiate from the regions just adjacent to the centrioles, which are moving closer to their poles. Some spindle fibres reach from pole to pole; most go to chromatids and attach at kinetochores.

(d) Metaphase. The chromosomes move toward the equator of the cell, where they become aligned in the equatorial plane. The sister chromatids have not yet separated.

(e) Anaphase. The two sister chromatids separate into independent chromosomes. Each contains a centromere that is linked by a spindle fibre to one pole, to which it moves. Thus one copy of each chromosome is donated to each daughter cell. Simultaneously, the cell elongates, as do the pole-to-pole spindles. Cytokinesis begins as the cleavage furrow starts to form.

(f) Telophase. New membranes form around the daughter nuclei; the chromosomes uncoil and become less distinct, the nucleolus becomes visible again, and the nuclear membrane forms around each daughter nucleus. Cytokinesis is nearly complete, and the spindle disappears as the microtubules and other fibres depolymerise. Throughout mitosis the "daughter" centriole at each pole grows until it is full-length. At telophase the duplication of each of the original centrioles is completed, and new daughter centrioles will be generated during the next interphase.

(g) Interphase. Upon the completion of cytokinesis, the cell enters the G₁ phase of the cell cycle and proceeds again around the cycle.

It will be appreciated that cell cycling is an extremely important cell process. Deviations from normal cell cycling can result in a number of medical disorders. Increased and/or unrestricted cell cycling may result in cancer. Reduced cell cycling may result in degenerative conditions. Use of the compound of the present invention may provide a means to treat such disorders and conditions.

Thus, the compound of the present invention may be suitable for use in the treatment of cell cycling disorders such as cancers, including hormone dependent and hormone independent cancers.

- 5 In addition, the compound of the present invention may be suitable for the treatment of cancers such as breast cancer, ovarian cancer, endometrial cancer, sarcomas, melanomas, prostate cancer, pancreatic cancer etc. and other solid tumours.

- 10 For some applications, cell cycling is inhibited and/or prevented and/or arrested, preferably wherein cell cycling is prevented and/or arrested. In one aspect cell cycling may be inhibited and/or prevented and/or arrested in the G₂/M phase. In one aspect cell cycling may be irreversibly prevented and/or inhibited and/or arrested, preferably wherein cell cycling is irreversibly prevented and/or arrested.

- 15 By the term "irreversibly prevented and/or inhibited and/or arrested" it is meant after application of a compound of the present invention, on removal of the compound the effects of the compound, namely prevention and/or inhibition and/or arrest of cell cycling, are still observable. More particularly by the term "irreversibly prevented and/or inhibited and/or arrested" it is meant that when assayed in accordance with the cell cycling assay
20 protocol presented herein, cells treated with a compound of interest show less growth after Stage 2 of the protocol I than control cells. Details on this protocol are presented below.

- Thus, the present invention provides compounds which: cause inhibition of growth of oestrogen receptor positive (ER+) and ER negative (ER-) breast cancer cells *in vitro* by
25 preventing and/or inhibiting and/or arresting cell cycling; and/or cause regression of nitroso-methyl urea (NMU)-induced mammary tumours in intact animals (i.e. not ovariectomised), and/or prevent and/or inhibit and/or arrest cell cycling in cancer cells; and/or act *in vivo* by preventing and/or inhibiting and/or arresting cell cycling and/or act as a cell cycling agonist.

CELL CYCLING ASSAY
(PROTOCOL 6)

Procedure

Stage 1

5

MCF-7 breast cancer cells are seeded into multi-well culture plates at a density of 105 cells/well. Cells were allowed to attach and grown until about 30% confluent when they are treated as follows:

10 Control - no treatment

Compound of Interest (COI) 20 μ M

Cells are grown for 6 days in growth medium containing the COI with changes of medium/COI every 3 days. At the end of this period cell numbers were counted using a

15 Coulter cell counter.

Stage 2

20 After treatment of cells for a 6-day period with the COI cells are re-seeded at a density of 10⁴ cells/well. No further treatments are added. Cells are allowed to continue to grow for a further 6 days in the presence of growth medium. At the end of this period cell numbers are again counted.

CANCER

25

As indicated, the compounds of the present invention may be useful in the treatment of a cell cycling disorder. A particular cell cycling disorder is cancer.

30 Cancer remains a major cause of mortality in most Western countries. Cancer therapies developed so far have included blocking the action or synthesis of hormones to inhibit the growth of hormone-dependent tumours. However, more aggressive chemotherapy is currently employed for the treatment of hormone-independent tumours.

35 Hence, the development of a pharmaceutical for anti-cancer treatment of hormone dependent and/or hormone independent tumours, yet lacking some or all of the side-

effects associated with chemotherapy, would represent a major therapeutic advance.

It is known that oestrogens undergo a number of hydroxylation and conjugation reactions after their synthesis. Until recently it was thought that such reactions were
5 part of a metabolic process that ultimately rendered oestrogens water soluble and enhanced their elimination from the body. It is now evident that some hydroxy metabolites (e.g. 2-hydroxy and 16alpha-hydroxy) and conjugates (e.g. oestrone sulphate, E1S) are important in determining some of the complex actions that oestrogens have in the body.

10

Workers have investigated the formation of 2- and 16-hydroxylated oestrogens in relation to conditions that alter the risk of breast cancer. There is now evidence that factors which increase 2-hydroxylase activity are associated with a reduced cancer risk, while those increasing 16alpha-hydroxylation may enhance the risk of breast cancer.
15 Further interest in the biological role of estrogen metabolites has been stimulated by the growing body of evidence that 2-methoxyoestradiol is an endogenous metabolite with anti-mitotic properties. 2-MeOE2 is formed from 2-hydroxy estradiol (2-OHE2) by catechol estrogen methyl transferase, an enzyme that is widely distributed throughout the body.

20

Workers have shown that *in vivo* 2-MeOE2 inhibits the growth of tumours arising from the subcutaneous injection of Meth A sarcoma, B16 melanoma or MDA-MB-435 estrogen receptor negative (ER-) breast cancer cells. It also inhibits endothelial cell proliferation and migration, and *in vitro* angiogenesis. It was suggested that the ability of
25 2-MeOE2 to inhibit tumour growth *in vivo* may be due to its ability to inhibit tumour-induced angiogenesis rather than direct inhibition of the proliferation of tumour cells.

The mechanism by which 2-MeOE2 exerts its potent anti-mitogenic and anti-angiogenic effects is still being elucidated. There is evidence that at high concentrations it can
30 inhibit microtubule polymerisation and act as a weak inhibitor of colchicine binding to tubulin. Recently, however, at concentrations that block mitosis, tubulin filaments in cells were not found to be depolymerised but to have an identical morphology to that seen after taxol treatment. It is possible, therefore, that like taxol, a drug that is used for breast and ovarian breast cancer therapy, 2-MeOE2 acts by stabilising microtubule
35 dynamics.

While the identification of 2-MeOE2 as a new therapy for cancer represents an important advance, the bioavailability of orally administered oestrogens is poor. Furthermore, they can undergo extensive metabolism during their first pass through the liver. As part of a research programme to develop a steroid sulphatase inhibitor for breast cancer therapy, oestrone-3-O-sulphamate (EMATE) was identified as a potent active site-directed inhibitor. Unexpectedly, EMATE proved to possess potent oestrogenic properties with its oral uterotrophic activity in rats being a 100-times higher than that of estradiol. Its enhanced oestrogenicity is thought to result from its absorption by red blood cells (rbcs) which protects it from inactivation during its passage through the liver and which act as a reservoir for its slow release for a prolonged period of time. A number of A-ring modified analogues were synthesised and tested, including 2-methoxyoestrone-3-O-sulphamate. While this compound was equipotent with EMATE as a steroid sulphatase inhibitor, it was devoid of oestrogenicity.

We believe that the compound of the present invention provides a means for the treatment of cancers and, especially, breast cancer.

In addition or in the alternative the compound of the present invention may be useful in the blocking the growth of cancers including leukaemias and solid tumours such as breast, endometrium, prostate, ovary and pancreatic tumours.

THERAPY CONCERNING OESTROGEN

We believe that some of the compounds of the present invention may be useful in the control of oestrogen levels in the body – in particular in females. Thus, some of the compounds may be useful as providing a means of fertility control – such as an oral contraceptive tablet, pill, solution or lozenge. Alternatively, the compound could be in the form of an implant or as a patch.

Thus, the compounds of the present invention may be useful in treating hormonal conditions associated with oestrogen.

In addition or in the alternative the compound of the present invention may be useful in treating hormonal conditions in addition to those associated with oestrogen. Hence, the

compound of the present invention may also be capable of affecting hormonal activity and may also be capable of affecting an immune response.

NEURODEGENERATIVE DISEASES

5

We believe that some of the compounds of the present invention may be useful in the treatment of neurodegenerative diseases, and similar conditions.

By way of example, it is believed that STS inhibitors may be useful in the enhancing the
10 memory function of patients suffering from illnesses such as amnesia, head injuries, Alzheimer's disease, epileptic dementia, presenile dementia, post traumatic dementia, senile dementia, vascular dementia and post-stroke dementia or individuals otherwise seeking memory enhancement.

15 TH1

We believe that some of the compounds of the present invention may be useful in TH1 implications.

20 By way of example, it is believed that the presence of STS inhibitors within the macrophage or other antigen presenting cells may lead to a decreased ability of sensitised T cells to mount a TH1 (high IL-2, IFN γ low IL-4) response. The normal regulatory influence of other steroids such as glucocorticoids would therefore predominate.

25

INFLAMMATORY CONDITIONS

We believe that some of the compounds of the present invention may be useful in treating inflammatory conditions – such as conditions associated with any one or more
30 of: autoimmunity, including for example, rheumatoid arthritis, type I and II diabetes, systemic lupus erythematosus, multiple sclerosis, myasthenia gravis, thyroiditis, vasculitis, ulcerative colitis and Crohn's disease, skin disorders e.g. psoriasis and contact dermatitis; graft versus host disease; eczema; asthma and organ rejection following transplantation.

35 By way of example, it is believed that STS inhibitors may prevent the normal

physiological effect of DHEA or related steroids on immune and/or inflammatory responses.

The compounds of the present invention may be useful in the manufacture of a
5 medicament for revealing an endogenous glucocorticoid-like effect.

OTHER THERAPIES

It is also to be understood that the compound/composition of the present invention may
10 have other important medical implications.

For example, the compound or composition of the present invention may be useful in the treatment of the disorders listed in WO-A-99/52890 – viz:

15 In addition, or in the alternative, the compound or composition of the present invention may be useful in the treatment of the disorders listed in WO-A-98/05635. For ease of reference, part of that list is now provided: cancer, inflammation or inflammatory disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response, cachexia, anorexia, acute infection, HIV
20 infection, shock states, graft-versus-host reactions, autoimmune disease, reperfusion injury, meningitis, migraine and aspirin-dependent anti-thrombosis; tumour growth, invasion and spread, angiogenesis, metastases, malignant, ascites and malignant pleural effusion; cerebral ischaemia, ischaemic heart disease, osteoarthritis, rheumatoid arthritis, osteoporosis, asthma, multiple sclerosis, neurodegeneration, Alzheimer's
25 disease, atherosclerosis, stroke, vasculitis, Crohn's disease and ulcerative colitis; periodontitis, gingivitis; psoriasis, atopic dermatitis, chronic ulcers, epidermolysis bullosa; corneal ulceration, retinopathy and surgical wound healing; rhinitis, allergic conjunctivitis, eczema, anaphylaxis; restenosis, congestive heart failure, endometriosis, atherosclerosis or endosclerosis.

30 In addition, or in the alternative, the compound or composition of the present invention may be useful in the treatment of disorders listed in WO-A-98/07859. For ease of reference, part of that list is now provided: cytokine and cell proliferation/differentiation activity; immunosuppressant or immunostimulant activity (e.g. for treating immune
35 deficiency, including infection with human immune deficiency virus; regulation of

lymphocyte growth; treating cancer and many autoimmune diseases, and to prevent transplant rejection or induce tumour immunity); regulation of haematopoiesis, e.g. treatment of myeloid or lymphoid diseases; promoting growth of bone, cartilage, tendon, ligament and nerve tissue, e.g. for healing wounds, treatment of burns, ulcers and
5 periodontal disease and neurodegeneration; inhibition or activation of follicle-stimulating hormone (modulation of fertility); chemotactic/chemokinetic activity (e.g. for mobilising specific cell types to sites of injury or infection); haemostatic and thrombolytic activity (e.g. for treating haemophilia and stroke); antiinflammatory activity (for treating e.g. septic shock or Crohn's disease); as antimicrobials; modulators of e.g. metabolism or
10 behaviour; as analgesics; treating specific deficiency disorders; in treatment of e.g. psoriasis, in human or veterinary medicine.

In addition, or in the alternative, the composition of the present invention may be useful in the treatment of disorders listed in WO-A-98/09985. For ease of reference, part of
15 that list is now provided: macrophage inhibitory and/or T cell inhibitory activity and thus, anti-inflammatory activity; anti-immune activity, i.e. inhibitory effects against a cellular and/or humoral immune response, including a response not associated with inflammation; inhibit the ability of macrophages and T cells to adhere to extracellular matrix components and fibronectin, as well as up-regulated fas receptor expression in T
20 cells; inhibit unwanted immune reaction and inflammation including arthritis, including rheumatoid arthritis, inflammation associated with hypersensitivity, allergic reactions, asthma, systemic lupus erythematosus, collagen diseases and other autoimmune diseases, inflammation associated with atherosclerosis, arteriosclerosis, atherosclerotic heart disease, reperfusion injury, cardiac arrest, myocardial infarction, vascular
25 inflammatory disorders, respiratory distress syndrome or other cardiopulmonary diseases, inflammation associated with peptic ulcer, ulcerative colitis and other diseases of the gastrointestinal tract, hepatic fibrosis, liver cirrhosis or other hepatic diseases, thyroiditis or other glandular diseases, glomerulonephritis or other renal and urologic diseases, otitis or other oto-rhino-laryngological diseases, dermatitis or other dermal
30 diseases, periodontal diseases or other dental diseases, orchitis or epididimo-orchitis, infertility, orchidal trauma or other immune-related testicular diseases, placental dysfunction, placental insufficiency, habitual abortion, eclampsia, pre-eclampsia and other immune and/or inflammatory-related gynaecological diseases, posterior uveitis, intermediate uveitis, anterior uveitis, conjunctivitis, chorioretinitis, uveoretinitis, optic
35 neuritis, intraocular inflammation, e.g. retinitis or cystoid macular oedema, sympathetic

ophthalmia, scleritis, retinitis pigmentosa, immune and inflammatory components of degenerative fundus disease, inflammatory components of ocular trauma, ocular inflammation caused by infection, proliferative vitreo-retinopathies, acute ischaemic optic neuropathy, excessive scarring, e.g. following glaucoma filtration operation, immune and/or inflammation reaction against ocular implants and other immune and inflammatory-related ophthalmic diseases, inflammation associated with autoimmune diseases or conditions or disorders where, both in the central nervous system (CNS) or in any other organ, immune and/or inflammation suppression would be beneficial, Parkinson's disease, complication and/or side effects from treatment of Parkinson's disease, AIDS-related dementia complex HIV-related encephalopathy, Devic's disease, Sydenham chorea, Alzheimer's disease and other degenerative diseases, conditions or disorders of the CNS, inflammatory components of stokes, post-polio syndrome, immune and inflammatory components of psychiatric disorders, myelitis, encephalitis, subacute sclerosing pan-encephalitis, encephalomyelitis, acute neuropathy, subacute neuropathy, chronic neuropathy, Guillain-Barre syndrome, Sydenham chora, myasthenia gravis, pseudo-tumour cerebri, Down's Syndrome, Huntington's disease, amyotrophic lateral sclerosis, inflammatory components of CNS compression or CNS trauma or infections of the CNS, inflammatory components of muscular atrophies and dystrophies, and immune and inflammatory related diseases, conditions or disorders of the central and peripheral nervous systems, post-traumatic inflammation, septic shock, infectious diseases, inflammatory complications or side effects of surgery, bone marrow transplantation or other transplantation complications and/or side effects, inflammatory and/or immune complications and side effects of gene therapy, e.g. due to infection with a viral carrier, or inflammation associated with AIDS, to suppress or inhibit a humoral and/or cellular immune response, to treat or ameliorate monocyte or leukocyte proliferative diseases, e.g. leukaemia, by reducing the amount of monocytes or lymphocytes, for the prevention and/or treatment of graft rejection in cases of transplantation of natural or artificial cells, tissue and organs such as cornea, bone marrow, organs, lenses, pacemakers, natural or artificial skin tissue.

30

COMPOUND PREPARATION

The compounds of the present invention may be prepared by reacting an appropriate alcohol with a suitable chloride. By way of example, the sulphamate compounds of the present invention may be prepared by reacting an appropriate alcohol with a suitable

35

sulfamoyl chloride, of the formula $R^4R^5NSO_2Cl$.

Typical conditions for carrying out the reaction are as follows.

- 5 Sodium hydride and a sulfamoyl chloride are added to a stirred solution of the alcohol in anhydrous dimethyl formamide at 0°C. Subsequently, the reaction is allowed to warm to room temperature whereupon stirring is continued for a further 24 hours. The reaction mixture is poured onto a cold saturated solution of sodium bicarbonate and the resulting aqueous phase is extracted with dichloromethane. The combined organic extracts are
- 10 dried over anhydrous $MgSO_4$. Filtration followed by solvent evaporation in vacuo and co-evaporated with toluene affords a crude residue which is further purified by flash chromatography.

- Preferably, the alcohol is derivatised, as appropriate, prior to reaction with the sulfamoyl
- 15 chloride. Where necessary, functional groups in the alcohol may be protected in known manner and the protecting group or groups removed at the end of the reaction.

- Preferably, the sulphamate compounds are prepared according to the teachings of Page *et al* (1990 Tetrahedron 46; 2059-2068).
- 20

The phosphonate compounds may be prepared by suitably combining the teachings of Page *et al* (1990 Tetrahedron 46; 2059-2068) and PCT/GB92/01586.

- The sulphonate compounds may be prepared by suitably adapting the teachings of
- 25 Page *et al* (1990 Tetrahedron 46; 2059-2068) and PCT/GB92/01586.

The thiophosphonate compounds may be prepared by suitably adapting the teachings of Page *et al* (1990 Tetrahedron 46; 2059-2068) and PCT/GB91/00270.

- 30 Preferred preparations are also presented in the following text.

SUMMARY

- In summation, the present invention provides novel compounds for use as steroid
- 35 sulphatase inhibitors and/or modulators of apoptosis and/or modulators of cell cycling

and/or cell growth, and pharmaceutical compositions containing them.

EXAMPLES


- 5 The present invention will now be described in further detail by way of example only with reference to the accompanying figure in which:-

Figure 1 shows a summary scheme.

- 10 The present invention will now be described only by way of example. However, it is to be understood that the examples also present preferred compounds of the present invention, as well as preferred routes for making same and useful intermediates in the preparation of same.


15 **Example 1 – Synthesis of 2-Methylsulfanyl-1,3,5[10]-estratriene-3-ol (7)**

17,17-Ethylenedioxy-1,3,5[10]-estratriene-3-ol



20

- A suspension of estrone (12.5g, 46.2 mmol), toluene (150 ml), ethylene glycol (14 ml) and tosic acid (120 mg) was refluxed for 14h under Dean-Stark conditions. The resultant pale pink transparent solution was poured onto saturated sodium bicarbonate solution (150 ml) and diluted with ethyl acetate (250 ml). The washed organic layer was separated and the aqueous residues extracted with a further aliquot of ethyl acetate (100 ml), the combined organics were washed with water (150 ml) and brine (150 ml), dried and evaporated to yield crude dioxolone (15 g, 103 %) as an off-white crystalline solid m.p. 183-184°C which was used without further purification (NMR shows purity >95%).
- 25


17,17-Ethylenedioxy-3-*O*-methoxymethylene-1,3,5[10]-estratriene

- 5 Sodium hydride (1.91 g, 47.7 mmol, 1.5 eq.) was added portion wise to a 0°C solution of the protected estrone (18.2 g, 58 mmol) in dimethylformamide (250 ml), after H₂ evolution had ceased methyl chloromethyl ether (8.81 ml, 2 eq.) was added in a dropwise manner and the stirred solution was allowed to come to room temperature overnight. The solution was then poured onto ammonia solution (100 ml, 2M) to destroy any remnant
- 10 haloether contaminants. Ethyl acetate (500 ml) was added and the aqueous layer removed, the organic layer was then washed with brine (5 x 200 ml) in a portion wise manner, dried and evaporated. The resultant pale yellow oil was purified by column chromatography (4:1 hexane:ethyl acetate, 10 cm diameter column, 20 cm bed depth) to give the product as a colourless oil (18.11g, 88 %) which solidified to give a white
- 15 crystalline solid m.p. 62-63°C. A further 1.6 g of product was obtained by repurification of mixed column fractions. m.p. 62-63°C, R_f 0.55 (3:1 Hex/EtOAc). δ_H (270 MHz, CDCl₃, ref. TMS = 0) 7.21 (1H, d, *J* 8.6, ArH), 6.82 (1H, d, *J* 8.6, ArH), 6.77 (1H, app s, ArH), 5.13 (2H, s, OCH₂O), 3.89-3.98 (4H, m, OCH₂CH₂O), 3.46 (3H, s, OCH₃), 2.83 (2H, cm, CH₂), 2.27 (2H, cm, CH₂), 1.25-2.05 (11H, m) and 0.88 (3H, s, CH₃). δ_C 155.0,
- 20 138.1, 134.0 (all C), 126.3 (CH), 119.4 (C), 116.2, 113.7 (both CH), 94.5, 65.2, 64.5 (all CH₂), 55.9 (CH₃), 49.3 (CH), 46.1 (C), 43.7, 38.9 (both CH), 34.2, 30.7, 29.7, 26.9, 26.1, 22.3 (all CH₂) and 14.3 (CH₃); MS [EI] 358.2(100 %, M⁺); HRMS [EI] 358.214410 C₂₂H₃₀O₄ requires 358.21441.

2-Methylsulfanyl-3-*O*-methoxymethylene-17,17-ethylenedioxy-1,3,5[10]-estratriene

- 5 A stirred solution of protected estrone (20 g, 55.8 mmol) in THF (400 ml) was cooled in a dry ice/acetone bath to -78°C before treating with *sec*-butyl lithium (129ml, 167 mmol, 1.3 M solution in cyclohexane) in a dropwise manner over a period of 1.5h. The anion was maintained at this temperature for a further hour before then quenching with dimethyl disulfide (20 ml, 223 mmol) over a period of five minutes and then allowed to
- 10 warm to room temperature over a further 2h. At this stage saturated ammonium chloride solution (25 ml) was added, the quenched solution diluted in diethyl ether (250 ml) and the organic layers were washed with saturated sodium hydrogen carbonate solution (3 x 150 ml), water (150 ml) and finally brine (150 ml) before drying (MgSO_4) and evaporating to yield a very pale yellow oil. Purification by gradient elution with
- 15 hexane/ethyl acetate mixtures (100:0 to 85:15) on silica gel gave a pure fraction of the desired sulphide (14.6 g, 36 mmol, 65%) as a clear colourless oil, a further batch of the sulphide (5.9g, 14.5 mmol) was recovered from the mixed by chromatography to give an overall yield of 20.5g, 91%.

20 2-Methylsulfanyl-1,3,5[10]-estratriene-3-ol (6)



- A 4M solution of methanolic HCl was prepared by cautious addition of acetyl chloride
- 25 (6.1 ml) to ice cold methanol (15.6 ml), after five minutes stirring this solution was poured onto protected estrone X (1.5g, 3.72 mmol). Sonication was applied to speed the


dissolution of the protected estrone, a pink colour emerged in the reaction mixture after five minutes and, after a further ten minutes, ethyl acetate (100 ml), and then sufficient sodium hydrogen carbonate to neutralise the reaction mixture was added. The organic layer was then washed with water (2 x 50 ml) and brine (100 ml) before drying (MgSO₄) and evaporating. Purification by gradient elution with hexane/ethyl acetate mixtures (100:0 to 80:20) on silica gel gave a white crystalline solid mp. 153-5°C which showed:

5 δ_H (400 MHz, CDCl₃) 7.40 (1H, s, OH), 6.73 (1H, s, ArH), 6.49 (1H, s, ArH), 2.82-2.91 (2H, m, 6-CH₂), 2.34-2.56 (2H, m), 2.30 (3H, s, SMe) 1.36-2.26 (11H, m) and 0.91 (3H, s, 18-CH₃); δ_C 226.4 (CO), 154.0, 139.8, 132.5 (all C), 131.9, 117.9 (both CH), 114.5 (C), 50.4 (CH), 48.0 (C), 43.9, 38.2 (both CH) 35.9, 31.6, 29.5, 26.5, 26.0, 21.7 (all CH₂) 20.3 (SCH₃) and 13.9 (CH₃); Calculated C, 72.11, H, 7.64; Found C 71.8 %, H, 7.70 %; MS[FAB⁺] 316.2 (100%, M⁺); HRMS[FAB⁺] 316.149702 calculated 316.14970.

10

2-Methylsulfanyl-3-O-sulfamoyl-1,3,5[10]-estratriene (7)

15



A stirred solution of 2-methylsulfanylestro-3-one (400 mg, 1.26 mmol) in dichloromethane (20 ml) was treated with 2,6-di-*tert*-butyl-4-methyl pyridine (776 mg, 3.78 mmol) at room temperature. After a further five minutes sulfamoyl chloride (5.4 ml, 3.78 mmol, 0.7M in toluene) was added in a dropwise manner and the resultant yellow solution was stirred for 16h. The reaction mixture was then poured onto water (25 ml), the organic layer separated and washed with water until neutral, dried and evaporated to give an oil. Column chromatography (chloroform: ethyl acetate 9:1) gave the desired sulfamates as a

20 white crystalline solid mp 184-5°C which showed δ_H (400 MHz, CD₃OD) 7.23 (1H, s, ArH), 7.12 (1H, s, ArH), 4.88 (2H, br s, NH₂), 2.82-2.90 (2H, m, 6-CH₂), 1.38-2.54 (16H, m [including 2.41 (3H, s, SMe)]) and 0.91 (3H, s, 18-CH₃); δ_C (100MHz, CD₃OD = 49.8) 220.2 (CO), 148.1, 140.6, 137.1, 130.7 (C), 126.9, 123.8, 52.4, 46.3, 40.2 (all CH), 37.5, 33.6, 30.8, 28.2, 27.8, 23.4 (all CH₂), 16.6 and 15.1 (both CH₃) NB. C-17

25

quaternary carbon lies under the resonance for CD₃OD; MS[FAB⁺] 395.2(M,55%), 255.2(170); [FAB⁺] 394.1 (100%); HRMS [FAB⁺] 395.12250, calculated 395.12250.

Example 2 – Synthesis of 2-Ethylsulfanyl-3-O-methoxymethylene-17,17-ethylenedioxy-1,3,5[10]-estratriene (9)


5

2-Ethylsulfanyl-3-O-methoxymethylene-17,17-ethylenedioxy-1,3,5[10]-estratriene




- 10 A stirred solution of protected estrone (5 g, 13.9 mmol) in THF (100 ml) was cooled in a dry ice/acetone bath to -78°C before treating with *sec*-butyl lithium (32.2 ml, 41.8 mmol, 1.3 M solution in cyclohexane) in a dropwise manner over a period of 0.5h. The anion was maintained at this temperature for a further hour and then quenched with diethyl disulfide (9.1 ml, 70 mmol) over a period of five minutes and then allowed to warm to
- 15 room temperature over a further 2h. At this stage saturated ammonium chloride solution (10 ml) was added, the quenched solution diluted in diethyl ether (100 ml) and the organic layers were washed with saturated sodium hydrogen carbonate solution (3 x 50 ml), water (50 ml) and finally brine (50 ml) before drying (MgSO₄) and evaporating to yield a very pale yellow oil. Purification by gradient elution with hexane/ethyl acetate
- 20 mixtures (100:0 to 85:15) on silica gel gave a pure fraction of the desired sulphide (5.3 g, 12.6 mmol, 97 %) as a clear colourless oil which showed 7.24 (1H, s, ArH), 6.82 (1H, s, ArH), 5.21 (2H, ArOCH₂), 3.86-3.98 (4H, m, OCH₂CH₂O), 3.51 (3H, s, OMe), 2.79-2.94 (4H, m, SCH₂ and 6-CH₂) 1.20-2.36 (16H, m [including 1.30 (3H, t, SCH₂CH₃) and 0.88 (3H, s, 18-CH₃); δ_{C} 153.3, 136.3, 134.2 (all C), 127.9 (CH), 121.9, 119.3 (both C), 115.0 (CH), 94.8, 65.3, 64.6 (all CH₂) 56.2 (CH₃), 49.3 (CH), 46.2 (C), 43.7, 38.9 (both CH),
- 25 34.3, 30.7, 29.6, 27.1, 27.0, 26.2, 22.4 (all CH₂), 14.4 and 14.3 (both CH₃)

2-Ethylsulfanyl-1,3,5[10]-estratriene-3-ol (8)



- 5 A 4M solution of methanolic HCl was prepared by cautious addition of acetyl chloride (6.1 ml) to ice cold methanol (15.6 ml), after five minutes stirring this solution was poured onto protected estrone X (1.8 g, 4.3 mmol). Sonication was applied to speed the dissolution of the protected estrone, a pink colour emerged in the reaction mixture after five minutes and, after a further ten minutes, ethyl acetate (100 ml), and then sufficient
- 10 sodium hydrogen carbonate to neutralise the reaction mixture was added. The organic layer was then washed with water (2 x 50 ml) and brine (100 ml) before drying (MgSO_4) and evaporating. Purification by crystallisation (ethanol) gave a yellow crystalline solid mp. 139-141°C which showed: δ_{H} (400 MHz, CDCl_3)
- 7.36 (1H, s, OH), 6.73 (1H, s, ArH), 6.57 (1H, s, ArH), 2.82-91 (2H, m, 6- CH_2), 2.66
- 15 (2H, q, J 7.4, SCH_2), 1.36-2.55 (13H, m), 1.21 (3H, t, J 7.4, SCH_2CH_3) and 0.91 (3H, s, 18- CH_3); δ_{C} 220.5 (CO), 154.7, 140.0 (both C), 133.0 (CH), 132.2 (C), 115.7 (CH), 114.3 (C), 50.4 (CH), 48.0 (C), 43.9 (CH), 38.2 (CH), 35.9, 31.6, 31.1, 29.5, 26.5, 26.0, 21.7 (all CH_2), 15.2 and 14.0 (both CH_3); MS[FAB $^+$] 330.2 (100%, M^+), HRMS[FAB $^+$] 330.165352, calculated 330.16535; Calculated C, 72.69, H, 7.93; Found C 72.9 %, H,
- 20 7.99 %.

2-Ethylsulfanyl-3-*O*-sulfamoyl-1,3,5[10]-estratriene (9)


25

A stirred solution of 2-ethylsulfanylestrone (300 mg, 0.91 mmol) in dichloromethane (20

ml) was treated with 2,6-di-*tert*-butyl-4-methyl pyridine (615 mg, 3 mmol) at room temperature. After a further five minutes sulfamoyl chloride (4.28 ml, 3 mmol, 0.7M in toluene) was added in a dropwise manner and the resultant yellow solution was stirred for 16h. The reaction mixture was then poured onto water (25 ml), the organic layer separated and washed with water until neutral, dried and evaporated to give an oil. Column chromatography (chloroform: ethyl acetate 9:1) gave the desired sulfamate as a white crystalline solid mp 179-181°C which showed δ_H 7.34 (1H, s, ArH), 7.16 (1H, s, ArH), 5.13 (2H, br s, NH₂), 2.86-2.98 (4H, m, SCH₂ and 6-CH₂), 1.40-2.57 (13H, m), 1.29 (3H, t, *J* 7.2, SCH₂CH₃) and 0.92 (3H, s, 18-CH₃); δ_C 220.3 (CO), 146.9, 139.5, 137.4 (all C), 129.1 (CH), 125.5 (C), 123.4 (CH), 50.4 (CH₂), 47.9 (C), 44.2, 37.0 (CH), 35.6, 31.6, 29.1, 28.0, 26.2, 25.9, 21.7 (all CH₂), 14.5 and 13.9 (both CH₃); MS[FAB⁺] 409.2 (100%, M⁺), HRMS[FAB⁺] found 409.13815, calculated 409.13815.

Example 3 – Synthesis of 2-Methylsulfanyl-3-*O*-sulfamoyl-17-deoxy-1,3,5[10]-estratriene (5)

3-*O*-Methoxymethylene-17-deoxy-1,3,5[10]-estratriene



A stirred, 0°C, solution of 17-deoxyestrone (3.12 g, 12.2 mmol), in dimethylformamide (50 ml) was treated sodium hydride (731 mg, 18.3 mmol) in a portion wise manner. After 0.5h stirring methyl chloromethyl ether (0.93 ml, 25 mmol) was added and the reaction mixture was left to stir overnight. Aqueous 2M ammonia (10 ml) was added to destroy excess chlorinated starting material and after a further 10 minutes ethyl acetate (200 ml) and brine (50 ml) were added. The organic layer was separated and washed five times with brine (50 ml aliquots), dried, evaporated and columned on silica gel (9:1 hexane:ethyl acetate as eluant) to give the desired protected 17-deoxyestrone as a clear colourless oil which showed δ_H 7.21 (1H, d, *J* 8.5), 6.82 (1H, dd, *J* 8.5 and 2.3, ArH),

6.77 (1H, d, J 2.3, ArH), 5.14 (2H, s, OCH₂O), 3.47 (3H, s, OCH₃), 2.78-2.86 (2H, m, 6-CH₂), 1.15-2.30 (15H, m) and 0.73 (3H, s, 18-CH₃); δ_C 154.8, 138.0, 134.3, 126.3, 116.1, 113.6, 94.4, 55.9, 53.6, 44.2, 41.1, 40.6, 39.1, 38.9, 30.0, 28.2, 26.8, 25.3, 20.7 and 17.7.

5 2-Methylsulfanyl-3-*O*-methoxymethylene-17-deoxy-1,3,5[10]-estratriene



A stirred solution of protected estrone (2.78 g, 9.35 mmol) in THF (100 ml) was cooled in a dry ice/acetone bath to -78°C before treating with *sec*-butyl lithium (28 ml, 21.5 mmol, 1.3 M solution in cyclohexane) in a dropwise manner over a period of 0.5h. The anion maintained at this temperature for 1 h and was then quenched with dimethyl disulfide (4.2 ml, 47 mmol) over a period of five minutes and then allowed to warm to room temperature over a further 2h. At this stage saturated ammonium chloride solution (10 ml) was added, the quenched solution diluted in diethyl ether (100 ml) and the organic layers were washed with saturated sodium hydrogen carbonate solution (3 x 50 ml), water (50 ml) and finally brine (50 ml) before drying (MgSO₄) and evaporating to yield the desired product as a spectroscopically pure yellow oil which showed δ_H 7.16 (1H, s, ArH), 6.81 (1H, s, ArH), 5.20 (2H, s, OCH₂O), 3.51 (3H, s, OMe), 2.78-2.86 (2H, m, 6-CH₂), 2.43 (3H, s, SMe), 1.10-2.36 (15H, m) and 0.74 (3H, s, 18CH₃).

20


2-Methylsulfanyl-17-deoxy-1,3,5[10]-estratrien-3-ol (4)



25 A 4M solution of methanolic HCl was prepared by cautious addition of acetyl chloride (6.1 ml) to ice cold methanol (15.6 ml), after five minutes stirring this solution was poured onto protected estrone X (1.8 g, 5.2 mmol). Sonication was applied to speed the

dissolution of the protected estrone, a pink colour emerged in the reaction mixture after five minutes and, after a further ten minutes, ethyl acetate (100 ml), and then sufficient sodium hydrogen carbonate to neutralise the reaction mixture was added. The organic layer was then washed with water (2 x 50 ml) and brine (100 ml) before drying (MgSO₄) and evaporating. Purification by column chromatography (8:1 hexane:ethyl acetate) gave a clear colourless oil which showed δ_H 7.41 (1H, s, OH), 6.78 (1H, s, ArH), 6.45 (1H, s, ArH), 2.78-2.85 (2H, m, 6-CH₂), 1.08-2.32 (18H, m [including 2.29 (3H, s, SMe)]) and 0.74 (3H, s, 18-CH₃); δ_C 153.7, 140.2, 133.6 (all C), 131.9 (CH), 117.4 (C), 114.4, 53.5, 43.9 (all CH), 41.0 (CH₂), 40.5, 39.0 (both CH), 38.8, 29.8, 28.0, 26.9, 25.3, 20.7 (all CH₂), 20.4 and 17.6 (both CH₃)

2-Methylsulfanyl-3-*O*-sulfamoyl-17-deoxy-1,3,5[10]-estratriene (5)




A stirred solution of 2-methylsulfanylestro-3-one (520 mg, 1.72 mmol) in dichloromethane (20 ml) was treated with 2,6-di-*tert*-butyl-4-methyl pyridine (883 mg, 4.3 mmol) at room temperature. After a further five minutes sulfamoyl chloride (6.15 ml, 4.3 mmol, 0.7M in toluene) was added in a dropwise manner and the resultant yellow solution was stirred for 16h. The reaction mixture was then poured onto water (25 ml), the organic layer separated and washed with water until neutral, dried and evaporated to give an oil. Column chromatography (chloroform: ethyl acetate 9:1) gave the desired sulfamates as a white foam (470 mg, 72%) which was crystallised from ethanol/hexane to give a white crystalline solid mp 119-120°C which showed δ_H 7.25 (1H, s, ArH), 7.10 (1H, s, ArH), 5.13 (2H, s, NH₂), 2.80-2.88 (2H, m, 6-CH₂), 2.46 (3H, s, SMe), 1.15-2.30 (15H, m) and 0.74 (3H, s, 18-CH₃); δ_C 145.6, 140.6, 136.7, 127.1, 126.1, 122.8, 53.5, 44.3, 41.0, 38.7, 38.6, 29.3, 27.8, 26.7, 25.2, 20.6, 17.5 and 16.2
MS[FAB⁺] 381.2 (100%, M⁺) and 301.2 (50%); HRMS [FAB⁺] found 381.143238,

calculated 381.14324.


Example 4 – Further Synthesis Examples

- 5 17-(4-tert-Butyl-benzyl)-13-methyl-2-methylsulfanyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol A




- 10 A solution of 4-(*t*-butyl) benzyl magnesium bromide was prepared by dropwise addition of an ethereal solution of 4-(*t*-butyl)benzyl bromide (3.67 ml, 20 mmol in 20 ml ether) to magnesium turnings (1.48g, 61 mmol) at room temperature over a period of 0.5 h. The resultant mixture was stirred for a further 2 h before adding 10 ml of the resultant solution of Grignard reagent to a rt stirred solution of 2-methylsulfanyl estrone (316 mg, 1mmol) in THF (20 ml). After overnight stirring the reaction was quenched with saturated ammonium chloride solution (10 ml), extracted with ethyl acetate (3 x 50 ml), the organic layer dried (MgSO₄) and evaporated. To facilitate chromatographic separation of product and starting material the crude product was dissolved in methanol (30 ml) and treated with sodium borohydride (75 mg, 2 mmol). After a standard work-up
- 15 the product was purified by column chromatography (hexane/ethyl acetate gradient elution) to give the desired product, 17-(4-tert-Butyl-benzyl)-13-methyl-2-methylsulfanyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cycl
- openta[a]phenanthrene-3,17-diol, as a white solid which showed δ_H 7.44 (1H, s, OH), 7.35 (2H, d, *J* 8.2, ArH), 7.22 (2H, d, *J* 8.2, ArH), 6.74 (1H, s, ArH), 6.49 (1H, s, ArH), 2.89 (1H, d, *J* 13.3, ArCH₂H_b), 2.84-2.89 (2H, m, 6-CH₂), 2.65 (1H, d, *J* 13.3, ArCH₂H_b), 1.26-2.42 (25H, m, including 2.31 (3H, s, SMe) and 1.34 (9H, s, CMe₃)) and 0.98 (3H, s, 18-CH₃); δ_C 153.9, 148.9, 140.1, 134.9, 133.2 (all C), 131.9, 130.5, 125.0 (all CH), 117.6 (C), 114.4 (CH), 82.9 (C), 49.5 (CH), 46.8 (C), 43.8 (CH), 41.9 (CH₂), 39.5 (CH), 34.5 (C), 33.8 (CH₂), 31.5 (CH₃), 31.4, 29.7, 27.4, 26.5, 23.4 (all CH₂), 20.4
- 25 and 14.6 (both CH₃).
- 30

Sulfamic acid 17-(4-tert-butyl-benzyl)-17-hydroxy-13-methyl-2-methylsulfanyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl ester **B**



The previously prepared estradiol (130 mg, 0.28 mmol) was dissolved in dichloromethane (10 ml) and treated with di-*t*-butyl methyl pyridine (172 mg, 0.84 mmol) and then sulfamoyl chloride (1.27 ml of a 0.7M solution in toluene, 0.89 mmol). After standard workup the desired product (42 mg) was isolated by column chromatography as a white powder mp. 135°C which showed δ_H 7.15-7.36 (6H, m, ArH), 5.08 (2H, s, NH₂), 2.84-2.95 (3H, m, ArCH and 6-CH₂), 2.61-2.66 (1H, m, ArCH), 2.48 (3H, s, SMe), 1.20-2.45 (23H, m, including 1.32 (9H, s, *t*Bu)) and 0.96 (3H, s, 18-CH₃): δ_C 149.1, 145.8, 140.2, 136.7, 134.7, 130.5, 127.3, 126.1, 125.0, 123.0, 109.7, 49.5, 46.7, 44.2, 41.8, 39.2, 34.5, 33.7, 31.5, 29.2, 27.3, 26.4, 23.4, 16.3, and 14.6.

17-Benzyl-13-methyl-2-methylsulfanyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol **C**




In the same manner as the synthesis of compound A 2-methylsulfanyl estrone (316 mg, 1 mmol) was reacted with benzyl magnesium chloride (5 ml of a two molar solution in THF) to give the desired estradiol as a white powder (200 mg) which showed δ_H 7.43 (1H, s, OH), 7.24-7.35 (5H, m, ArH), 6.73 (1H, s, ArH), 6.48 (1H, s, ArH), 2.93 (1H, d, *J* 13.3, PhH_aH_b), 2.84-2.89 (2H, m, 6-CH₂) 2.67 (1H, d, *J* 13.3, PhH_aH_b), 1.26-2.42 (17 H, m, including 2.31 (3H, s, SMe)) and 0.97 (3H, s, 18-CH₃); δ_C 153.9, 140.1, 138.2, 133.2,

65

131.9, 130.9, 128.0, 126.2, 117.2, 114.4, 83.0, 49.6, 46.9, 43.9, 42.5, 39.6, 33.9, 31.5, 29.7, 27.5, 26.5, 23.4, 20.4 and 14.6.

Sulfamic acid 17-benzyl-17-hydroxy-13-methyl-2-methylsulfanyl-7,8,9,11,12,13,14,
5 15,16,17-decahydro-6H-cyclopenta[a]phenanthren-3-yl ester



In the same manner as the synthesis of compound B estradiol C (142 mg, 0.348 mmol)
10 was reacted with DBMP (214 mg, 1.04 mmol) and sulfamoyl chloride (1.59 ml of 0.7M
toluene solution, 1.11 mmol) to obtain sulfamate D (40 mg) as a white powder mp 178-
180°C.

Example 4 – Biological Data

15

The compounds identified in the table below were synthesised.

| | Compound | X | Y | Z |
|--|----------|----------------------------------|-----|-------------------|
| | 1 | OSO ₂ NH ₂ | SMe | β-OH, α-Bn |
| | 2 | OH | SMe | β-OH, α-4-(tBu)Bn |
| | 3 | OSO ₂ NH ₂ | SMe | β-OH, α-4-(tBu)Bn |
| | 4 | OH | SMe | CH ₂ |
| | 5 | OSO ₂ NH ₂ | SMe | CH ₂ |
| | 6 | OH | SMe | C=O |
| | 7 | OSO ₂ NH ₂ | SMe | C=O |
| | 8 | OH | SEt | C=O |
| | 9 | OSO ₂ NH ₂ | SEt | C=O |

20

The STS inhibition provided by the compounds was determined in accordance with the placental microsomes assay of Protocol 2 and a plate assay.

| Compound | Placental Microsomes, % inhibition | | | | | Plate Assay, % inhibition | | |
|----------|------------------------------------|-----------|-------|------|--------|---------------------------|-----------|------------|
| | 10 μ M | 1 μ M | 100nM | 10nM | IC50nM | 0.1 μ M | 1 μ M | 10 μ M |
| 1 | 97.4 | 93.0 | 69.7 | 15.5 | 44 | <1 | <1 | 31 |
| 2 | - | - | - | - | - | <1 | <1 | 50 |
| 3 | 86.4 | 81.8 | 56.0 | 17.6 | 80 | <1 | <1 | 48 |
| 6 | - | - | - | - | - | <1 | 1 | 11 |
| 7* | - | 86.9 | - | 5.4 | 120 | 3 | 53 | 55 |
| 8 | - | - | - | - | - | <1 | <4 | 14 |
| 9 | - | 66.0 | - | <5 | - | <1 | 1 | 16 |
| EMATE | 99.5 | 97.8 | 85.1 | 27.3 | 18 | - | - | - |

* IC50 2.5 nM T47D cells.

5 EXAMPLE 5 - Cell cycle and Apoptosis Analysis

MCF7, CAL51, CAMA1 and ZR-75-1 breast cancer derived cell lines were obtained from ATCC (MCF7, CAMA1, ZR-75-1) or from the Dutrillaux laboratory (CAL51) (22) and maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with
10 10% (v/v) fetal calf serum and antibiotics.

DNA content was determined by flow cytometric analysis of propidium iodide stained cells and TdT-mediated dUTP-nick end labelling (TUNEL), respectively, as described (20). The proportion of cells in G2/M phase of the cell cycle was calculated as a
15 proportion of cells with 2N to 4N DNA content. The proportion of cells with <G1 DNA content was calculated as a percentage of total cells.

To determine the proportion of cells in mitosis, drug treated cells were collected by trypsinisation and cytopspins prepared. Cells were fixed in ice cold methanol for 5
20 minutes, air dried and DNA was stained using propidium iodide (PI) (0.1 mg/ml in phosphate buffered saline (PBS) containing 10% (v/v) newborn calf serum and 0.05% (w/v) sodium azide). Cells were analysed by confocal microscopy using a Zeiss Axiovert 100 M microscope equipped with the LSM 510 confocal system (Zeiss, Jena, Germany).

25 We examined whether the differential sensitivity of breast cancer cell lines to the growth inhibitory effects of the compounds of the present invention. Compounds of the present invention were shown to have such an effect. In particular Compound 7 induced cells to become rounded and detached from the plate/flask, indicating that the cells were


undergoing microtubule disruption, mitotic/cell cycle arrest and apoptosis.

5 All publications and patents and patent applications mentioned in the above specification are herein incorporated by reference.

10 Various modifications and variations of the present invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in chemistry, biology or related fields are intended to be within the scope of the following claims.

CLAIMS

1. A compound of Formula I




Formula I

wherein:

- 5 X is a ring having at least 4 atoms in the ring;
 K is a hydrocarbyl group;
 R¹ is an optional group of the formula -L¹-S-R^{1'}, wherein L¹ is an optional linker group and R^{1'} is a hydrocarbyl group;
 R² is an optional group of the formula -L²-S-R^{2'}, wherein L² is an optional linker group and R^{2'} is a hydrocarbyl group;
 10 R³ is any one of a sulphamate group, a phosphonate group, a thiophosphonate group, a sulphonate group or a sulphonamide group;
 wherein at least one of R¹ and R² is present;
 and wherein said compound is capable of inhibiting steroid sulphatase (STS) activity
 15 and/or is capable of acting as a modulator of cell cycling and/or as a modulator of apoptosis and/or as a modulator of cell growth.

2. A compound according to claim 1 having Formula II




Formula II

- 20 3. A compound according to claim 1 or 2 wherein X in combination with K mimics a steroidal structure.
4. A compound according to any one of the preceding claims wherein K is a cyclic group.
- 25 5. A compound according to any one of the preceding claims wherein X is a six-

membered ring.

6. A compound according to claim 5 having Formula III


Formula III



5 7. A compound according to any one of the preceding claims wherein X in combination with K is a steroidal ring structure.

8. A compound according to claim 7 having Formula IV

Formula IV



10 9. A compound according to any one of the preceding claims wherein R³ is a sulphamate group.

10. A compound according to any one of the preceding claims wherein R¹ and/or R² are alkyl groups.


15

11. A compound according to any one of the preceding claims wherein R¹ and/or R² are C₁-C₁₀, preferably C₁-C₆, preferably C₁-C₃ alkyl groups.


12. A compound according to any one of the preceding claims wherein R¹ and/or R² are -CH₃ or -CH₂CH₃.

20

13. A compound according to claim 1 of the formula



14. A compound according to claim 1 of the formula



- 5 15. A method comprising (a) performing a steroid sulphotase assay with one or more candidate compounds having the formula as defined in any one of the preceding claims; (b) determining whether one or more of said candidate compounds is/are capable of modulating STS activity and/or cell cycling and/or cell growth and/or apoptosis; and (c) selecting one or more of said candidate compounds that is/are capable of modulating
10 STS activity and/or cell cycling and/or cell growth and/or apoptosis.

16. A method comprising (a) performing a steroid sulphotase assay with one or more candidate compounds having the formula as defined in any one of claims 1 to 14; (b) determining whether one or more of said candidate compounds is/are capable of
15 inhibiting STS activity; and (c) selecting one or more of said candidate compounds that is/are capable of inhibiting STS activity and/or cell cycling and/or cell growth and/or apoptosis.

- 20 17. A compound identified by the method according to claim 15 or claim 16.

18. A compound according to any one of claims 1 to 14 or 17 for use in medicine.


- 25 19. A pharmaceutical composition comprising the compound according to any one of claims 1 to 14 or 17 optionally admixed with a pharmaceutically acceptable carrier, diluent, excipient or adjuvant.

20. Use of a compound according to any one of claims 1 to 14 or 17 in the manufacture of a medicament for use in the therapy of a condition or disease associated with STS and/or cell cycling and/or apoptosis and/or cell growth.

- 30 21. Use of a compound according to any one of claims 1 to 14 or 17 in the

manufacture of a medicament for use in the therapy of a condition or disease associated with adverse STS levels and/or cell cycling and/or apoptosis and/or cell growth.

A flexible entry to substituted estrones



Ability to selectively access a wide range of substituted estrones through the utilisation of a bis-protected estrone intermediate which can be lithiated in a regiospecific manner and subsequently quenched with a wide range of electrophiles. This is an efficient way for us to access 2-Methoxy and 2-EthylEstrone, it has also allowed us to synthesize several new classes of compounds, some of which display high biological activity.

INTERNATIONAL SEARCH REPORT

In: onal Application No
PCT/GB 01/03705

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07J41/00 A61K31/565 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07J A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, PAJ, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|--|-----------------------|
| Y | WO 98 24802 A (POTTER BARRY VICTOR LLOYD ; REED MICHAEL JOHN (GB); IMPERIAL COLLEG) 11 June 1998 (1998-06-11) page 22; table 1 | 1-21 |
| Y | PUROHIT A ET AL: "RECENT ADVANCES IN THE DEVELOPMENT OF STEROID SULPHATASE INHIBITORS" JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 69, no. 1/6, 1999, pages 227-238, XP000852540 ISSN: 0960-0760 page 228; example 4 page 233, column 1, paragraphs 1,2 -/-- | 1-21 |

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * & * document member of the same patent family

Date of the actual completion of the international search

12 November 2001

Date of mailing of the international search report

03/12/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Watchorn, P

INTERNATIONAL SEARCH REPORT

In International Application No
PCT/GB 01/03705

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| Y | WO 99 33858 A (STANFORD RES INST INT) 8 July 1999 (1999-07-08) page 93, line 15-17; examples 21-23 | 1-21 |
| Y | DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PUROHITT, ATUL ET AL: "The effect of 2-methoxyoestrone-3-O-sulphamate on the growth of breast cancer cells and induced mammary tumours" retrieved from STN Database accession no. 133:38406 XP002182502 abstract & INT. J. CANCER (2000), 85(4), 584-589 , | 1-21 |
| Y | DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SINGH, A. ET AL: "Inhibition of deoxyglucose uptake in MCF-7 breast cancer cells by 2-methoxyestrone and 2-methoxyestrone-3-O-sulfamate" retrieved from STN Database accession no. 132:318130 XP002182503 abstract & MOL. CELL. ENDOCRINOL. (2000), 160(1-2), 61-66 , | 1-21 |
| Y | PUROHIT A ET AL: "THE DEVELOPMENT OF A-RING MODIFIED ANALOGUES OF OESTRONE-3-O- SULPHAMATE AS POTENT STEROID SULPHATASE INHIBITORS WITH REDUCED OESTROGENICITY" JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, ELSEVIER SCIENCE LTD., OXFORD, GB, vol. 64, no. 5, 1998, pages 269-275, XP000852539 ISSN: 0960-0760 page 270, column 2; figure 1; example 2 page 272, column 2, paragraph 2 | 1-21 |
| Y | US 6 011 024 A (POTTER BARRY VICTOR LLOYD ET AL) 4 January 2000 (2000-01-04) column 56; table 1 | 1-21 |
| Y | WO 99 64013 A (POTTER BARRY VICTOR LLOYD ; REED MICHAEL JOHN (GB); STERIX LTD (GB)) 16 December 1999 (1999-12-16) page 23, last paragraph page 25, line 1-5 | 1-21 |
| | --- -/-- | |

INTERNATIONAL SEARCH REPORT

In International Application No
PCT/GB 01/03705

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

| Category * | Citation of document, with indication, where appropriate, of the relevant passages | Relevant to claim No. |
|------------|---|-----------------------|
| Y | HOWARTH N M ET AL: "ESTRONE SULFAMATES: POTENT INHIBITORS OF ESTRONE SULFATASE WITH THERAPEUTIC POTENTIAL" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 37, no. 2, 21 January 1994 (1994-01-21), pages 219-221, XP000652211 ISSN: 0022-2623 page 220; figures 3,4 | 1-21 |
| Y | CUSHMAN M ET AL: "SYNTHESIS, ANTITUBULIN AND ANTIMITOTIC ACTIVITY, AND CYTOTOXICITY OF ANALOGS OF 2-METHOXYESTRADIOL, AN ENDOGENOUS MAMMALIAN METABOLITE OF ESTRADIOL THAT INHIBITS TUBULIN POLYMERIZATION BY BINDING TO THE COLCHICINE BINDING SITE" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 38, no. 12, 1995, pages 2041-2049, XP002055798 ISSN: 0022-2623 page 2043; example 15; table 1 | 1-21 |

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1-12,15-21 (in part)

Present compound claims 1-14 relate to a compound defined by reference to a desirable characteristic or property, namely that the compounds according to this very broad formula:

- (i) are capable of inhibiting steroid sulphatase (STS), and/or
- (ii) are capable of acting as a modulator of cell cycling and/or
- (iii) are capable of acting as a modulator of apoptosis and/or
- (iv) are capable of acting as a modulator of cell growth

This is a functional definition of the claimed compounds which limits the extremely broad Markush formula of this claim to those compounds which possess one or more of the above activities. In this regard it is noted that provision of agents with the above activities is in fact the problem to be solved (see page 3, lines 8-10 of the description). The Markush formula of claim 1 is so broad that it has no technical meaning in the sense of providing a solution to the technical problem without further limiting it by means of the above functional feature to only those compounds conforming to this formula which solve the problem. Consequently claim 1 and claims 2-12 dependent thereon have been defined in terms of being a solution to the problem - a clear desideratum. Consequently the claims cover all compounds having this activity, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims 1-12 which appear to be clear, supported and disclosed, namely those parts relating to 2-S-hydrocarbyl derivatised *estra-1,3,5(10)-triene-3-sulphamates*, which covers all those compounds of the examples and the compounds of claims 13 and 14 in full.

The search on the diagnostic claims 15 and 16 and the first and second medicinal use claims 18, 20 and 21 as well as the pharmaceutical composition claims of claim 19 has been limited to uses/diagnostics/compositions of the compounds of claims 1-12 which were searched (see above paragraph).

Furthermore, claim 17 relates to compounds defined purely by means of their discovery according to the diagnostic method of claim 15 or 16 (a so-called "reach-through claim"). Since the diagnostic methods specified in claims 15 and 16 are those for uncovering compounds with the

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

activities used to define the compounds of claim 1, claim 17 has exactly the same scope as claim 1 and as such the search on this claim has been restricted in exactly the same way as that on claim 1 (see first paragraph above).

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

In International Application No

PCT/GB 01/03705

| Patent document cited in search report | | Publication date | Patent family member(s) | Publication date |
|---|---|---------------------|---|--|
| WO 9824802 | A | 11-06-1998 | AU 5402398 A EP 0942919 A2 WO 9824802 A2 JP 2001505221 T | 29-06-1998 22-09-1999 11-06-1998 17-04-2001 |
| WO 9933858 | A | 08-07-1999 | US 6046186 A AU 1941699 A EP 1042354 A2 WO 9933858 A2 | 04-04-2000 19-07-1999 11-10-2000 08-07-1999 |
| US 6011024 | A | 04-01-2000 | US 5830886 A US 6159960 A US 6187766 B1 US 2001018435 A1 AT 194843 T AU 717116 B2 AU 1007799 A AU 668882 B2 AU 2490592 A AU 689043 B2 AU 5837396 A AU 7195298 A BR 9206434 A CA 2114630 A1 CZ 9400440 A3 DE 69231280 D1 DE 69231280 T2 DK 641355 T3 EP 1099706 A2 EP 0641355 A1 EP 0928609 A2 EP 0921130 A2 EP 0982032 A2 ES 2148178 T3 FI 940903 A FI 20002259 A FI 20002260 A FI 20002261 A WO 9305064 A1 GR 3034579 T3 HU 66097 A2 JP 2000038341 A JP 7501515 T JP 2000355542 A JP 2000355598 A KR 258396 B1 LV 12618 A LV 12618 B NO 940635 A NO 995075 A NO 995076 A NO 2595 A SK 24694 A3 US 5616574 A | 03-11-1998 12-12-2000 13-02-2001 30-08-2001 15-08-2000 16-03-2000 04-03-1999 23-05-1996 05-04-1993 19-03-1998 05-09-1996 13-08-1998 27-09-1994 18-03-1993 18-01-1995 24-08-2000 30-11-2000 09-10-2000 16-05-2001 08-03-1995 14-07-1999 09-06-1999 01-03-2000 16-10-2000 20-04-1994 13-10-2000 13-10-2000 13-10-2000 18-03-1993 31-01-2001 28-09-1994 08-02-2000 16-02-1995 26-12-2000 26-12-2000 01-08-2000 20-02-2001 20-07-2001 29-04-1994 29-04-1994 29-04-1994 29-04-1994 09-11-1994 01-04-1997 |
| WO 9964013 | A | 16-12-1999 | AU 4280799 A EP 1085876 A1 WO 9964013 A1 | 30-12-1999 28-03-2001 16-12-1999 |